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Abstract
Invasive fungal infections are a significant cause of morbidity and mortality in children. Successful 
management of these systemic infections requires identification of the causative pathogen, 
appropriate antifungal selection, and optimisation of its pharmacokinetic and pharmacodynamic 
properties to maximise its antifungal activity and minimise toxicity and the emergence of 
resistance. This review highlights salient scientific advancements in paediatric antifungal 
pharmacotherapies and focuses on pharmacokinetic and pharmacodynamic studies that underpin 
current clinical decision making. Four classes of drugs are widely used in the treatment of invasive 
fungal infections in children, including the polyenes, triazoles, pyrimidine analogues and 
echinocandins. Several lipidic formulations of the polyene amphotericin B have substantially 
reduced the toxicity associated with the traditional amphotericin B formulation. Monotherapy with 
the pyrimidine analogue flucytosine rapidly promotes the emergence of resistance and cannot be 
recommended. However, when used in combination with other antifungal agents, therapeutic drug 
monitoring of flucytosine has been shown to reduce high peak flucytosine concentrations, which 
are strongly associated with toxicity. The triazoles feature large inter-individual pharmacokinetic 
variability, although this pattern is less pronounced with fluconazole. In clinical trials, 
posaconazole was associated with fewer adverse effects than other members of the triazole family, 
though both posaconazole and itraconazole display erratic absorption that is influenced by gastric 
pH and the gastric emptying rate. Limited data suggest that the clinical response to therapy may be 
improved with higher plasma posaconazole and itraconazole concentrations. For voriconazole, 
pharmacokinetic studies among children have revealed that children require twice the 
recommended adult dose to achieve comparable blood concentrations. Voriconazole clearance is 
also affected by the cytochrome P450 (CYP) 2C19 genotype and hepatic impairment. Therapeutic 
drug monitoring is recommended as voriconazole pharmacokinetics are highly variable and small 
dose increases can result in marked changes in plasma concentrations. For the echinocandins, the 
primary source of pharmacokinetic variability stems from an age-dependent decrease in clearance 
with increasing age. Consequently, young children require larger doses per kilogram of body 
weight than older children and adults. Routine therapeutic drug monitoring for the echinocandins 
is not recommended. The effectiveness of many systemic antifungal agents has been correlated 
with pharmacodynamic targets in in vitro and in murine models of invasive candidiasis and 
aspergillosis. Further study is needed to translate these findings into optimal dosing regimens for 
children and to understand how these agents interact when multiple antifungal agents are used in 
combination.
1 Introduction
Invasive fungal infections are a leading cause of mortality among immunocompromised and 
critically ill children [1]. The most common aetiological agents of invasive fungal infections 
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are Candida and Aspergillus, which despite prompt antifungal therapy have mortality rates 
of 30–80 % [2–6]. It is therefore desirable to consider antifungal pharmacokinetics and 
pharmacodynamics, which have the potential to inform the development of dosing regimens 
that can improve antifungal activity and minimize toxicity [7].
Currently, four broad classes of systemic antifungal agents are used in the treatment of 
invasive fungal infections, including the polyenes, triazoles, pyrimidine analogues, and 
echinocandins [8]. The polyenes and triazoles target key components of the fungal cell 
membrane (Fig. 1) [9]. The pyrimidine analogue flucytosine inhibits DNA and RNA 
synthesis, which disrupts protein synthesis and cellular division [10]. The echinocandins are 
a recently discovered class of antifungal agents that interfere with cell wall biosynthesis 
[11]. Each of these classes exhibits unique pharmacokinetic and pharmacodynamic 
characteristics, which have been the subject of varying degrees of scientific investigation.
Pharmacokinetic and pharmacodynamic relationships have been defined for several 
antifungal agents that have been used to predict responses to treatment [12, 13]. In 
evaluating these pharmacodynamic relationships, three patterns of antifungal activity have 
been defined: (1) concentration-dependent activity, where antifungal activity increases with 
higher drug concentrations (e.g. polyenes and echinocandins); (2) time-dependent activity 
with little to no post-antifungal effect, where higher antifungal concentrations do not 
increase the rate or extent of antifungal activity and there is negligible antifungal activity 
when drug concentrations fall below the minimum inhibitory concentration (MIC) (e.g. 
flucytosine); and (3) time-dependent activity with prolonged post-antifungal effects, where 
fungal growth is suppressed for a period of time after the drug concentration falls below the 
MIC (e.g. triazoles) [14, 15]. However, it must be noted that post-antifungal effects are often 
pathogen specific [16, 17]. To define the pharmacodynamic pattern that best describes the 
antifungal activity of a given drug dose fractionation studies are often performed, in which a 
variety of doses are administered at multiple dosing intervals (Fig. 2). If regimens with 
shorter dosing intervals are more efficacious, then the time-dependent pharmacodynamic 
parameter (T > MIC) is the most important parameter, as in the case of flucytosine [12]. 
When large, infrequently administered doses are the most efficacious, then the ratio of the 
maximum concentration (Cmax) to the MIC (Cmax)/MIC) is the most important 
pharmacodynamic parameter, as in the case of the polyenes and echinocandins [15, 18, 19]. 
Lastly, when antifungal activity is comparable for each of the dosing intervals, then the 
clinical outcome is most dependent on the total dose or the area under the plasma 
concentration–time curve (AUC) in relation to the MIC (AUC/MIC) [20]. Dose fractionation 
studies have found that this pattern of activity is correlated with the clinical response to 
therapy for the triazoles [13, 21]. Both in vivo and in vitro experiments have shown that the 
pharmacodynamic parameter that is best correlated with the response to treatment and its 
relative magnitude are comparable for drugs within the same class, when unbound drug 
concentrations are evaluated [22]. Additionally, extensive studies conducted with 
antibacterials have demonstrated that the correlation between pharmacodynamic target 
attainment and clinical outcomes is remarkably conserved across species, dosing intervals 
and infection foci [22, 23]. This may reflect the fact that the targets of antimicrobial 
therapies are within the infecting organism and thus do not vary as a consequence of 
differing host species [24]. Additionally, pharmacodynamic targets are often formulated as a 
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function of the unbound drug concentration and therefore account for inter- and intra-species 
pharmacokinetic differences [24].
For well-studied conditions, such as disseminated candidiasis, a bridging approach has 
proven effective in extending results obtained from studies conducted in animal models to 
the clinic [25]. For children, this often involves extrapolation of efficacy from studies in 
adults [26]. Recent guidelines from the US FDA and the European Medicines Agency 
(EMA) have recognised that this approach may be considered in cases where the drug is to 
be used for the same indication(s), the disease process is similar, and the outcome of therapy 
is comparable. Successful examples can be found in the field of antifungal pharmacology 
with respect to the development of caspofungin and micafungin [27, 28]. These drugs were 
licensed for paediatric use following a series of systematic investigations in phase I–III 
clinical trials, which established age-specific population pharmacokinetics, determined 
appropriate paediatric doses, and collected limited safety and efficacy data needed to support 
the feasibility of extrapolating data from large randomised trials conducted in adults [29–
31]. Despite these and other recent successes, many of the older antifungal agents have never 
been licensed for paediatric use and remain understudied. A list of antifungal agents that 
have been approved by the FDA for the treatment of invasive fungal infections is featured in 
Table 1.
Understanding the pharmacokinetics and pharmacodynamics of antifungal agents used 
across the paediatric age spectrum represents a major challenge as human growth during the 
first two decades of life is dynamic and nonlinear [32]. For the safe and effective treatment 
of invasive fungal infections it is necessary to evaluate drug absorption, distribution, 
metabolism and elimination throughout childhood [33]. In this review, we comprehensively 
evaluate the pharmacokinetic and pharmacodynamic literature describing the four most 
common classes of antifungal agents and describe paediatric-specific considerations in their 
pharmacokinetics, pharmacodynamics and therapeutic drug monitoring. Each section 
concludes with an evaluation of current knowledge gaps and highlights areas for future 
research. Published reports were systematically identified using the search terms ‘paediatric’ 
or ‘pediatric’ or ‘children’ and the generic and trade names for each antifungal agent in 
PubMed and EBSCOhost. When no paediatric studies were identified, the query was 
modified to remove the paediatric-specific search terms. Identified articles were then 
reviewed and evaluated by at least two authors and duplicate publications were excluded 
from further review. The literature search was finalised on 1 November 2013 and no limits 
were applied on the basis of publication date.
2 Polyenes
Polyene macrolides are the oldest class of antifungal agents and have been used for more 
than 50 years, primarily due to their broad spectrum of activity [34–36]. The most common 
systemically administered drug in this class is amphotericin B deoxycholate [37]. 
Amphotericin B binds to fungal membrane ergosterols, which results in increased cell 
permeability and ultimately cell death [38]. Although amphotericin B binds to fungal 
membrane sterols with high affinity, it also binds to cholesterol components of mammalian 
cells and therefore is commonly associated with toxic adverse events [36].
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In an effort to alleviate concerns regarding toxicity, several lipid-based formulations of 
amphotericin B have been developed [39]. The reformulation of amphotericin B into a 
liposomal carrier (liposomal amphotericin B) or a lipid complex with a ribbon-like 
(amphotericin B lipid complex) or disk-like (amphotericin B colloidal dispersion) shape 
alters the pharmacokinetic and pharmacodynamic properties of these drugs. Critically, in 
comparison to conventional amphotericin B deoxycholate, these three commercially 
produced lipidic formulations are associated with less toxicity [37].
2.1 Pharmacokinetics and Pharmacodynamics
Amphotericin B deoxycholate is administered parenterally as it exhibits negligible 
gastrointestinal absorption [38]. Upon entering the bloodstream, amphotericin B rapidly 
dissociates from the deoxycholate, where >90 % of the drug binds to serum proteins [38]. 
Amphotericin B distributes widely into tissues, particularly the liver and spleen (Table 2)
[40]. In adults, amphotericin B features a distribution phase of 15–48 h and a terminal 
elimination half-life of approximately 15 days [41]. Similar distribution phase kinetics have 
been reported for pre-term neonates, infants, and children 4 months to 14 years of age [42, 
43]. Among children, the terminal elimination phase half-life of amphotericin B has been 
reported to range from weeks to months [42]. Amphotericin B poorly penetrates into the 
cerebrospinal fluid (CSF), vitreous humour or amniotic fluid [44]. Excretion into the urine is 
also negligible [38].
The clinical utility of amphotericin B deoxycholate is limited due to the drug’s narrow 
therapeutic window, which requires clinicians to carefully balance efficacy and toxicity [39]. 
Adverse events commonly include acute infusion-related toxicity and nephrotoxicity [45, 
46]. Within the last 10 years, several studies demonstrated that continuous infusion of 
amphotericin B deoxycholate may reduce the incidence of nephrotoxicity and infusion-
related adverse reactions [47–51]. However, amphotericin B has been shown to feature 
concentration-dependent antifungal activity in vitro, which suggests that infrequent 
administration of large amphotericin B doses may optimise its pharmacodynamic activity 
[15]. Moreover, amphotericin B exhibits non-linear, concentration-dependent protein 
binding in plasma and tissues [52]. Few pharmacokinetic and pharmacodynamic studies 
have accounted for the influence of physiologically relevant concentrations of human serum 
albumin when comparing amphotericin B dosing regimens. However, in the single study 
conducted to date, Lewis et al. [53] developed an in vitro pharmacodynamic model to 
compare continuous versus rapid infusion strategies with varying concentrations of human 
serum albumin. The authors found that the antifungal activity of amphotericin B was 
dramatically reduced or completely ablated in the presence of human serum albumin 
concentrations ranging from 4 to 8 %. The authors further reported no difference in the rate 
or extent of amphotericin B antifungal activity with rapid or continuous infusion regimens. 
These findings suggest that extended or continuous infusion strategies may reduce the 
incidence of toxic adverse events, although such regimens are unlikely to optimise 
amphotericin B pharmacodynamics and may result in treatment failure.
For patients who are refractory to or intolerant of conventional amphotericin B 
deoxycholate, several lipidic formulations may be considered. The pharmacokinetic 
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properties of these lipid-based formulations differ markedly when compared to amphotericin 
B deoxycholate [38].
Amphotericin B lipid complex pharmacokinetics have been extensively studied in mice, rats, 
rabbits and dogs [54, 55]. Following administration of a single dose of amphotericin B lipid 
complex, amphotericin B concentrations were substantially lower in the liver, spleen and 
lungs than concentrations measured following administration of amphotericin B 
deoxycholate [55]. Comparable concentrations were measured in the kidneys [55]. In 
plasma, amphotericin B lipid complex achieved higher amphotericin B concentrations than 
conventional amphotericin B deoxycholate [55]. As the dose of amphotericin B lipid 
complex is increased, amphotericin B concentrations in the liver, spleen and lung tissue 
increase markedly; however, no change is observed in amphotericin B concentrations in the 
kidneys or in the plasma [55]. In a murine model system, the half-maximal lethal dose 
(LD50) following a single intravenous dose of amphotericin B deoxycholate was determined 
to be 3 mg/kg, whereas the LD50 of amphotericin B lipid complex was established at 40 
mg/kg [56]. In multiple-dose studies, amphotericin B lipid complex continued to exhibit 
significantly reduced toxicity in mice and rabbits when compared to amphotericin B 
deoxycholate [56, 57]. In humans, the pharmacokinetics of amphotericin B lipid complex 
are similar to those reported in animal studies [58].
Amphotericin B colloidal dispersion pharmacokinetics have also been extensively studied in 
animal models [59–61]. Following a single intravenous bolus, amphotericin B colloidal 
dispersion resulted in significantly lower plasma amphotericin B concentrations than dosing 
with amphotericin B deoxycholate in rats [59]. The terminal elimination half-life is also 
longer and the volume of distribution is considerably larger [59]. In dogs, administration of 
amphotericin B colloidal dispersion resulted in increased amphotericin B concentrations in 
the liver, comparable concentrations in the plasma and decreased concentrations in the 
kidney when compared with dosing with amphotericin B deoxycholate [60]. In further 
single- and multiple-dose experiments across several species, amphotericin B colloidal 
dispersion consistently demonstrated less toxic effects than amphotericin B deoxycholate 
[61]. As yet, few human trials have investigated the pharmacokinetics of amphotericin B 
colloidal dispersion; however, safety and efficacy trials have demonstrated that amphotericin 
B colloidal dispersion displays comparable antifungal activity and less nephrotoxicity than 
amphotericin B at clinically relevant doses [62].
The pharmacokinetics of liposomal amphotericin B have been studied in mice, rats and 
rabbit models of invasive fungal infection [63, 64]. Liposomal amphotericin B is negatively 
charged and considerably smaller than the two lipid complex formulations of amphotericin 
B (amphotericin B lipid complex and amphotericin B colloidal dispersion), which may 
retard its uptake within the reticuloendothelial system [65]. This may explain, in part, why 
liposomal amphotericin B achieves far higher peak amphotericin B plasma concentrations 
and features a prolonged circulation time when compared to amphotericin B lipid complex 
and amphotericin B colloidal dispersion [65]. In mice and rats, liposomal amphotericin B is 
less nephrotoxic, with an LD50 50-fold lower than that of amphotericin B deoxycholate [63]. 
However, slight elevations in liver transaminases have also been reported following the 
administration of multiple doses of liposomal amphotericin B [63]. In a small human 
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autopsy study, liposomal amphotericin B achieved the highest amphotericin B 
concentrations in the liver and the spleen, which is consistent with previous findings from 
animal models [66]. Using a two-compartment model, liposomal amphotericin B 
pharmacokinetic parameters were established for a cohort of 44 immunocompromised adults 
[67]. The authors found that liposomal amphotericin B exhibits a non-linear dose-response 
relationship that was consistent with reticuloendothelial uptake and redistribution [67]. Hong 
et al. [68] evaluated the population pharmacokinetics of liposomal amphotericin B among 39 
children with neoplastic disease and found that weight exerted a significant influence upon 
both clearance and the volume of distribution in the central compartment. In simulations, the 
authors found that weight-related changes in liposomal amphotericin B pharmacokinetic 
parameters alter drug exposure, such that children <20 kg require a higher dose to achieve 
peak amphotericin B concentration targets.
2.2 Intra- and Inter-Individual Variability
The disposition of amphotericin B deoxycholate is more variable among neonates and young 
children than in adolescents and adults [69]. Serum half-lives were reported to be longer in 
four of five neonates than in older children [69]. Following 5 days of therapy, inter-
individual variability in amphotericin B clearance was high among 13 neonates [42]. 
Pharmacokinetic evaluations conducted with amphotericin B lipid complex also revealed 
evidence of substantial inter-individual variability in clearance and volume of distribution 
(35 and 43 %, respectively) [70]. These data suggest that younger children have a greater 
potential for drug accumulation and heightened inter-individual variability than adults [37]. 
Additionally, amphotericin B deoxycholate CSF concentrations are 2–4 % of serum 
concentrations in adults; however, CSF penetration may be as high as 40 % among pre-term 
neonates [42, 71].
2.3 Dosing Optimisation
Amphotericin B features a broad spectrum of activity and is an established agent in the 
treatment of endemic and opportunistic invasive fungal infections; however, up to 80 % of 
patients experience infusion-related toxicity or nephrotoxicity [36, 72]. Although 
nephrotoxicity is typically less severe in infants and children, efforts are needed to optimise 
the dosing of amphotericin B to improve its tolerability [37]. To this end, several studies 
have administered amphotericin B deoxycholate by continuous infusion, as opposed to 
traditional 2–6 h infusions [49, 51, 73, 74]. These studies reported a decrease in the rate of 
nephrotoxicity and fewer infusion-related reactions when compared with a 4-h infusion at 
the same daily dose [51]. Despite these promising findings, however, continuous infusion of 
amphotericin B has not been widely adopted due to challenges in obtaining venous access 
solely for the purpose of administering the drug and pharmacodynamic data that suggest that 
amphotericin B is most efficacious when higher daily doses are administered less frequently 
[15, 24, 51].
In an effort to enhance the efficacy of amphotericin B dosing regimens, the randomised 
multicentre AmBiLoad trial evaluated a high loading dose of liposomal amphotericin B at 10 
mg/kg/day for the first 14 days of therapy as compared with standard dosing regimens of 3 
mg/kg/day [75]. At the end of study drug treatment, the primary endpoint was assessed as 
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complete or partial response to therapy, along with secondary survival and safety outcomes. 
The authors found that liposomal amphotericin B at 3 mg/kg/day yielded a response rate of 
50 % and a 12-week survival rate of 72 %. The high loading dose regimen did not improve 
clinical outcomes and resulted in higher rates of nephrotoxicity.
2.4 Therapeutic Drug Monitoring
Therapeutic drug monitoring for amphotericin B deoxycholate is of limited utility due to the 
absence of a well-defined correlation between measured amphotericin B concentrations and 
clinical efficacy [76]. Moreover, at doses that are routinely administered clinically, plasma 
concentrations rarely exceed 1–2 μg/mL [77]. On the basis of these findings, in 1991 the 
Working Party of the British Society for Antimicrobial Chemotherapy concluded that 
therapeutic drug monitoring of amphotericin B deoxycholate is unnecessary [78]. More 
recent studies have sought to determine whether plasma or serum amphotericin B 
concentrations correlate with nephrotoxicity [79, 80]. These studies concluded that 
amphotericin B-induced nephrotoxicity was correlated with the total cumulative dose, rather 
than serum concentrations. To date, amphotericin B plasma or serum concentrations have 
not been correlated with clinical efficacy or toxicity, such that therapeutic drug monitoring 
cannot be recommended. Limited paediatric pharmacokinetic data suggest that the intra-
individual variability observed with the lipidic formulations of amphotericin B may be larger 
than the inter-individual variability, confounding dose individualisation efforts through 
therapeutic drug monitoring [68, 81].
2.5 Drug Resistance
Despite more than 50 years of widespread clinical use, fungal resistance to amphotericin B 
is rare [82]. In a recent study of more than 9,000 Candida albicans isolates, 99.8 % remained 
sensitive to amphotericin B [83]. Resistance is most frequently encountered in isolates of 
Candida lusitaniae, Aspergillus terreus and Aspergillus nidulans [84]. In in vitro 
experiments, mutant isolates that display resistance to amphotericin B and nystatin develop 
compensatory mechanisms to replace ergosterol with precursor sterols [85]. Due to the 
relative scarcity of polyene-resistant fungal strains, it has been speculated that the fitness 
cost incurred by developing this adaptive form of resistance attenuates the pathogenicity of 
ergosterol-deficient mutants [86].
2.6 Clinical Recommendations and Prospects for Future Research
As equally effective, less toxic antifungal agents have been developed, it is now unlikely that 
further characterisation of amphotericin B deoxycholate pharmacokinetics and 
pharmacodynamics will occur [87]. However, further evaluation of lipidic formulations of 
amphotericin B is warranted due to their improved toxicity profile and equivalent efficacy 
[88, 89]. These agents are typically employed as salvage therapies for patients who are 
refractory to or intolerant of amphotericin B deoxycholate, primarily owing to their high 
cost. Consequently, few studies have sought to establish correlations between 
pharmacokinetic profiles and clinical outcomes. As the costs of these agents decrease, such 
studies will be invaluable in guiding clinical decision making.
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3 Pyrimidine Analogues
Flucytosine (5-fluorocytosine, 5-FC) is a pro-drug that is actively transported into fungal 
cells by cytosine permease [90]. Cytosine deaminase converts flucytosine to 5-fluorouracil, 
which can subsequently be converted to 5-fluorouridine triphosphate for incorporation 
within fungal RNA (thereby inhibiting protein synthesis), or be converted to 5-
fluorodeoxyuridine monophosphate and inhibit thymidylate synthetase (thereby inhibiting 
DNA synthesis) [10, 91, 92].
3.1 Pharmacokinetics and Pharmacodynamics
Flucytosine is administered orally with >70 % absorption, although absorption can be 
delayed by renal insufficiency, antacids and food [93, 94]. Flucytosine is not highly bound 
by serum proteins, is highly water soluble, and penetrates well into the CSF, vitreal humour, 
peritoneal fluid as well as the synovial fluid of inflamed joints [93, 95–98]. Peak 
concentrations are reached within 1–2 h post-administration and it is recommended that 
serum concentrations be maintained between 40 and 80 μg/mL [93, 99]. Flucytosine is 
primarily eliminated by the kidneys via glomerular filtration, such that its clearance is 
closely correlated with serum creatinine concentrations [93, 97, 100].
Flucytosine is rarely used as a monotherapy due to the emergence of rapid antifungal 
resistance during treatment [101–105]. However, flucytosine is thought to be synergistic 
with amphotericin B, which facilitates its penetration into fungal cells [106]. Concentrations 
of amphotericin B are increased in the CSF, heart valves and the vitreal body when 
coadministered with flucytosine [101]. There are sparse pharmacokinetic data on flucytosine 
in paediatric patients. In adults, the serum half-life of flucytosine is 3–6 h in patients with 
normal renal function, but is extended in patients with impaired renal function (up to 85 h) 
[97]. A neonatal pharmacokinetic study demonstrated that the half-life was twice that 
reported in adults, although peak concentrations were comparable [42]. Additionally, the 
volume of distribution of flucytosine approximates the volume of total body water due to its 
high solubility [103]. In a retrospective study of 391 paediatric patients, 65 % of flucytosine 
trough concentrations exceeded the normal reference range in children 1–30 days of age 
[107]. These data suggest that the standard dose of 100 mg/kg/day may not be appropriate 
and that further studies are needed to establish optimal age-appropriate dosing regimens.
3.2 Intra- and Inter-Individual Variability
High inter-individual variability exists with paediatric patients. Baley et al. [42] reported that 
three infants had an extended half-life up to 35 h, which they attributed to immature kidney 
function.
3.3 Dosing Optimisation
Due to the prolonged half-life of flucytosine in paediatric patients, it has been suggested that 
dosing intervals can be as long as 24 h without compromising its fungistatic activity, despite 
adult recommendations for 6-hourly dosing [42]. Additionally, the synergistic effect of 
amphotericin B and flucytosine achieves the same therapeutic target with lower doses [10, 
108].
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3.4 Therapeutic Drug Monitoring
When using flucytosine, it is important to monitor plasma concentrations to avoid toxicity. 
High peak serum concentrations have resulted in hepatic injury, bone marrow suppression 
and gastrointestinal disturbances [109–112]. In addition, renal insufficiency can be induced 
by amphotericin B co-treatment and commonly leads to toxicity as a consequence of 
decreased renal clearance.
3.5 Drug Resistance
Resistance is common with flucytosine and typically occurs through mutations in cytosine 
permease (decreases drug uptake into fungal cells), increased synthesis of pyrimidines 
(decreases competitive inhibition) or, most commonly, through mutations in uridine 
monophosphate pyrophosphorylase, which decrease the metabolism of flucytosine to its 
active antimetabolite [94, 113, 114]. Both high and low flucytosine concentrations have been 
demonstrated to incur resistance [114]. Nearly 8 % of C. albicans and Torulopsis glabrata 
strains are intrinsically resistant, whereas only 1–2 % of Candida neoformans strains are 
resistant [115]. Between 8 and 44 % of non-albicans Candida species have been reported to 
be resistant to flucytosine [116].
3.6 Clinical Recommendations and Prospects for Future Research
Flucytosine monotherapy is not recommended due to the rapid emergence of resistance and 
therefore it is unlikely that feature studies will evaluate flucytosine pharmacokinetics in 
isolation. However, further studies are needed in children to understand the mechanism and 
effects of flucytosine and amphotericin B synergy. Pharmacokinetic and pharmacodynamic 
studies will be vitally important in establishing an optimal dosing regimen for these two 
agents [104]. Further investigation of combination therapies with triazoles is also warranted.
4 Triazoles
The triazoles feature broad antifungal activity and are well-tolerated [117]. These agents 
interfere with fungal-specific cytochrome P450 (CYP) activity (lanosterol 14-α-
demethylase), which then inhibits cell membrane ergosterol synthesis [118]. Ergosterol 
synthesis is essential to maintain normal membrane permeability [119]. Triazole-mediated 
inhibition of ergosterol synthesis alters fungal membrane permeability and results in cell 
death.
The most commonly prescribed triazole agents include fluconazole, itraconazole, 
voriconazole and posaconazole [120]. Collectively, these drugs represent a major advance in 
paediatric antifungal therapy, although historically their use has been marked by the 
emergence of resistance and drug-drug interactions [117]. Fluconazole features activity 
against many Candida species, but has little or no activity against Candida krusei, Candida 
glabrata and most filamentous fungi, including Aspergillus [121]. Newer triazole agents, 
such as posaconazole, display potent in vitro activity against pathogenic yeasts and moulds, 
including fluconazole-resistant strains of Candida and Zygomycetes [122].
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4.1 Pharmacokinetics and Pharmacodynamics
Fluconazole is available for parenteral and oral administration and is well-absorbed from the 
gastrointestinal tract (Table 3)[123]. Fluconazole is a hydrophilic drug and 11–13 % of the 
drug binds to serum proteins [124, 125]. In adults, fluconazole distributes into a volume 
similar to that of total body water (approximately 0.71 L/kg) [126]. However, the apparent 
volume of distribution in immunocompromised paediatric patients varies by age, with the 
largest volume of distribution reported among neonates, which decreases with increasing age 
until adult levels are reached in adolescence [127]. Fluconazole is widely distributed to 
nearly all organs and tissues, including the central nervous system (CNS) [119]. Fluconazole 
also undergoes minimal metabolism and is primarily excreted unchanged in the urine [125, 
128]. The longest half-life has been observed among neonates, which then declines to 21–23 
h among children 3 months to 16 years of age and rises again to approximately 30 h among 
adults [127, 129, 130]. These age-specific pharmacokinetic differences suggest that the 
increased volume of distribution in children will result in lower systemic fluconazole 
concentrations than in adults who receive a proportional dose [127]. Additionally, the shorter 
half-life among children (with the exception of neonates) has the potential to result in 
reduced drug accumulation if adult once-daily dosing regimens are extrapolated to children 
[127].
Itraconazole is available in a capsular, oral and intravenous formulation [131]. The capsular 
formulation is characterised by erratic absorption and variable plasma concentrations [132]. 
More recently developed oral and intravenous formulations display less variable 
pharmacokinetics [117]. Itraconazole is a highly lipophilic drug that is nearly insoluble in 
water [133]. Gastric emptying rates affect itraconazole dissolution in the stomach and its 
absorption from the small intestine [133]. Upon entering the bloodstream itraconazole 
rapidly binds to red blood cells and circulating plasma proteins [134]. Consequently, 
unbound concentrations of itraconazole in the CSF, vitreal fluid and saliva are markedly 
lower than unbound plasma concentrations [134]. Following a single dose, peak 
concentrations are reached within 2–3 h post-administration and the terminal elimination 
half-life is approximately 25 h [135]. Itraconazole is extensively metabolised in the liver, 
primarily by CYP3A4, for which itraconazole is both a substrate and an inhibitor [136]. Due 
to CYP3A4 auto-inhibition, the half-life of itraconazole has been found to increase to more 
than 30 h in patients following a week of therapy [137].
Due to the highly variable absorption profile of the capsular formulation of itraconazole, 
most paediatric studies have characterised the pharmacokinetics of the oral and intravenous 
formulations of itraconazole [135, 138, 139]. de Repentigny and colleagues [138] 
administered oral itraconazole at 5 mg/kg once daily for 2 weeks to 26 infants and children 6 
months to 12 years of age who were at risk for invasive fungal infections. The authors 
reported lower Cmax and AUC from time zero to 24 h (AUC24) values among children 6 
months to 2 years of age on the first day of therapy, although these differences resolved by 
day 14. When compared to repeated-dose pharmacokinetic studies among adults who 
received oral itraconazole at 5 mg/kg, the Cmax and AUC24 among children were 
approximately one third of the values measured among adults [138, 140, 141]. Similar 
results were reported in a subsequent study conducted among 26 HIV-infected children and 
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adolescents 5–18 years of age [135]. More recently, the single-dose pharmacokinetics of an 
intravenous formulation of itraconazole were evaluated among 33 children 7 months to 17 
years of age [139]. Itraconazole Cmax and AUC24 values were higher in children who 
received the intravenous formulation than in previous studies conducted using the oral 
formulation. However, as itraconazole undergoes significant first-pass hepatic inactivation 
(approximately 50 %), this was not unexpected [142]. The authors found no evidence that 
age influenced itraconazole pharmacokinetics, suggesting that weight-based dosing of 
intravenous itraconazole may be employed irrespective of the age of the child being treated 
[139].
Voriconazole is available in both an oral and an intravenous formulation [143]. In healthy 
volunteers, the oral formulation of voriconazole displays high bioavailability (>90 %) and 
moderate protein binding (58 %) [144]. Unlike itraconazole, pharmacokinetic studies in 
adults have revealed evidence of high inter-individual variability with both voriconazole 
formulations [145, 146]. A non-linear dose-exposure relationship has been reported that may 
be attributable to saturation of hepatic metabolizing enzymes [143]. Pharmacogenetic 
studies have demonstrated that genetic differences in CYP2C19 expression contributes to the 
inter-individual variability observed in voriconazole pharmacokinetics [147–150]. Genetic 
variants in CYP2C19 are common and are known to alter voriconazole metabolism [151]. 
Using adult doses, paediatric pharmacokinetic studies have described a linear non-saturable 
dose-exposure profile for children <5 years of age [152]. However, at higher recommended 
doses, children exhibit non-linear voriconazole pharmacokinetics in the majority of children 
[153]. As a consequence of differences in the degree of non-linearity in voriconazole 
pharmacokinetics between children and adults, paediatric patients require more than twice 
the adult dose to achieve comparable blood concentrations [154]. Recently, several 
paediatric studies have reported an association between improved patient outcomes and a 
voriconazole trough concentration > 1 μg/mL [155–157]. However, high inter-individual 
variability makes it challenging to reliably attain this trough target in clinical practice. 
Michael et al. [153] reported trough concentrations < 0.1 μg/mL and as high as 16.3 μg/mL 
in two toddlers who received the same 7 mg/kg intravenous dose.
Posaconazole is the most recently developed member of the triazole class and is currently 
available as an oral suspension and a delayed-release tablet [158, 159]. The oral absorption 
of posaconazole is variable (8–47 %) and may be altered in patients with poor appetite, 
nausea, diarrhoea, gastrointestinal disorders, and in patients receiving concurrent acid-
suppressive therapies [160]. However, the bioavailability of the posaconazole suspension can 
be greatly enhanced when it is administered after a high-fat meal [161]. Administration 
every 6 or 8 h with food has been shown to increase posaconazole exposure by 180 % when 
compared with once-daily dosing [162]. Notably, the recently approved delayed-release 
tablet formulation of posaconazole features improved bioavailability, no food effect and 
decreased inter-individual variability when compared with the oral suspension [159, 163, 
164]. Similar to the other members of the triazole family, posaconazole inhibits CYP3A4; 
however, unlike voriconazole, CYP2C9, CYP2C19 and other CYP isoenzymes are not 
affected [165, 166]. Posaconazole has a large volume of distribution at steady state and has 
been reported to feature high alveolar penetration with concentrations in pulmonary alveoli 
that are approximately 35-fold higher than plasma concentrations [167]. However, the extent 
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to which posaconazole crosses the blood–brain barrier is unknown. Up to 20–30 % of the 
posaconazole dose is metabolised by uridine diphosphate (UDP)-glucuronosyltransferase 
UGT1A4 (the glucuronide conjugates possess minimal antifungal activity) [168] and the 
remaining 70–80 % is eliminated unchanged in the faeces [158, 169]. To date, the few 
studies available report no obvious pharmacokinetic differences between children and adults 
[170].
4.2 Intra- and Inter-Individual Variability
Triazole pharmacokinetics are influenced by pathophysiologic considerations, including 
small bowel resection, graft versus host disease, fluid overload and gastroenteritis [76]. 
Although specific pharmacokinetic differences exist in certain patient populations, 
fluconazole pharmacokinetics are generally less variable than those in other triazole agents 
[77, 129]. However, the volume of distribution of fluconazole among children is larger and 
marked by increased variability when compared with adult patients [171].
Itraconazole is an extremely weak base and is only ionised in acidic environments [172]. For 
this reason, the capsular formulation of itraconazole features variable dissolution in the 
stomach before being absorbed from the small bowel [133]. Additionally, itraconazole is 
both an inhibitor and a substrate of the drug transporter P-glycoprotein (P-gp) [173]. The 
expression level of P-gp expression found on the apical membrane of mature enterocytes 
may play a significant role in itraconazole absorption. This is especially relevant in critically 
ill children where P-gp expression has been found to vary up to tenfold [174]. Similarly, 
itraconazole is both a substrate and an inhibitor of CYP3A4 [173]. Itraconazole-induced 
inhibition of CYP3A4 may result in increased plasma concentrations of other medications 
that are metabolised by CYP3A4, including: midazolam, atazanavir, ritonavir, tacrolimus, 
cyclosporine (ciclosporin) and others (Table 4) [175].
The factors contributing to the high inter- and intraindividual variability in voriconazole 
pharmacokinetics are poorly understood in children [176]. A multicentre retrospective 
review evaluated voriconazole pharmacokinetics among 139 children with invasive 
aspergillosis and found that published doses ranged from 3.4 to 23 mg/kg/day [177]. Despite 
this wide range in administered voriconazole doses, target troughs >1 μg/mL were rarely 
achieved [155, 178, 179]. Moreover, among those children who did achieve target trough 
concentrations, the weight-adjusted doses varied widely. In two additional studies recently 
conducted among paediatric haematopoietic stem cell transplant patients, less than half of 
the patients studied achieved and sustained a therapeutic trough concentration without 
individualised voriconazole concentration monitoring and dose adjustment [157, 180]. To 
better elucidate the factors affecting voriconazole pharmacokinetics in children, Karlsson et 
al. [181] conducted a population pharmacokinetic analysis using data from three studies 
conducted among children 2–11 years of age who received a range of single or multiple 
intravenous and/or oral voriconazole doses. The authors reported that the CYP2C19 
genotype and blood ALT concentration significantly influenced voriconazole clearance 
[181]. Similar to other triazole agents, drug-drug interactions can significantly alter 
voriconazole exposure [154]. In one such study, the coadministration of phenobarbital 
caused a 50 % reduction in the voriconazole Cmax [182].
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Variability in posaconazole pharmacokinetics occurs primarily as a consequence of altered 
absorption [170]. This phenomenon is more pronounced in critically ill patient populations, 
including those with gastric mucosal alterations such as chemotherapy-associated mucositis 
[143]. In one adult study, allogeneic bone marrow transplant recipients had posaconazole 
concentrations that were 52 % lower than those measured among non-transplanted febrile 
neutropenic patients [183]. The authors also reported a larger inter-individual coefficient of 
variation (71–82 %). In a study of 12 children and 194 adults, mean posaconazole plasma 
concentrations were comparable [170]. The youngest study participant was 8 years old and 
had a mean steady-state posaconazole plasma concentration of 227 ng/mL, which was 
comparable with the mean steady-state concentration measured among the oldest paediatric 
participant (238 ng/mL) [170]. This finding suggests that posaconazole pharmacokinetics 
are similar among older children and adults; however, posaconazole pharmacokinetics have 
not been studied among children <8 years of age.
4.3 Dosing Optimisation
As invasive fungal infections often occur in immunocompromised patients or those with 
concomitant bacterial infections, it is challenging to evaluate the clinical response to 
antifungal therapy [184]. However, in a study of 28 adult cancer patients with presumed or 
proven mould infections, the total daily dose of fluconazole was increased to 1,200, 1,600 
and 2,000 mg, which was associated with Cmax values of 51.8, 74.4 and 91.8 mg/L, 
respectively [185]. Less than one third of the patients in each dosing group responded to 
therapy, implying that the clinical response is not dose—and therefore concentration—
dependent. However, in this study rates of adverse events were observed to increase with 
larger doses [185]. Dosages up to 1,600 mg/day were well-tolerated, although larger doses 
were associated with neurotoxicity [185].
Guidelines from the Infectious Disease Society of America (IDSA) recommend that adults 
with candidaemia who receive treatment with fluconazole be given a loading dose on the 
first day of therapy [186, 187]. In the only paediatric study to date, Piper et al. [188] 
evaluated the pharmacokinetics and safety of a 25 mg/kg loading dose among eight infants 
<60 days of age with serial fluconazole serum concentration measurements. The authors 
found that five of eight (63 %) infants achieved the therapeutic exposure target (AUC24 > 
400 mg·h/L) and 100 % achieved a 24-h trough concentration > 8 μg/mL. The three infants 
who did not achieve the AUC target were receiving extracorporeal membrane oxygenation 
(n = 1), were severely oedematous (n = 1) or immunocompromised (n = 1). Larger loading 
doses may be warranted for these special patient populations.
There are no published itraconazole pharmacodynamic studies among children with invasive 
fungal infections. However, a single study examined the pharmacodynamics of oral 
itraconazole among HIV-infected children and adolescents with oropharyngeal candidiasis 
[135]. As predicted from murine dose fractionation studies, the pharmacodynamic parameter 
that was most closely correlated with the response to treatment was the AUC12 (r = 0.595; P 
= 0.01) [135].
In vivo experiments in animal models of invasive candidiasis have demonstrated a strong 
relationship between voriconazole exposure and treatment efficacy [21]. Similar to other 
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triazoles, the unbound voriconazole AUC/MIC needed to produce a half-maximal antifungal 
effect was approximately 25 [21]. For adults with disseminated candidiasis, a voriconazole 
AUC/MIC <25 was associated with treatment failure in 40–50 % of the patients studied 
[189]. Among patients with invasive aspergillosis, a trough voriconazole concentration > 0.5 
μg/mL was associated with a trend toward a higher odds of treatment success (odds ratio 1.5; 
95 % CI 0.6–3.4) [190]. In a more recent study of 52 patients who received more than 2,000 
days of voriconazole therapy for the treatment of invasive fungal infections, trough 
concentrations < 1 μg/mL were associated with a positive outcome in approximately 50 % of 
cases as compared to 90 % among patients with troughs ≥1 μg/mL [156]. In a recent 
paediatric study, a trough voriconazole concentration < 1 μg/mL was associated with a 2.6-
fold increased odds of death (95 % CI 1.6–4.8; P = 0.002) [155]. In Monte-Carlo 
simulations, the authors found that an intravenous dose of 7 mg/kg or an oral dose of 200 mg 
every 12 h would be predicted to achieve a trough > 1 μg/mL in 66 % of patients, although 
predicted trough concentrations were highly variable [155]. In another paediatric study, the 
clinical outcomes of 30 immunocompromised patients who received a combined 2,135 days 
of voriconazole therapy were evaluated [191]. No statistically significant relationship was 
found between voriconazole concentrations and overall mortality; however, a higher 
percentage of subtherapeutic plasma concentrations was observed in those who died [191]. 
Among children < 5 years of age, the median dose that yielded trough concentrations > 1 
μg/mL was 19 mg/kg every 12 h, which is more than double the current recommended dose 
for this age group [155, 191].
Few studies have examined the relationship between posaconazole exposure and clinical 
efficacy in adults and none have been conducted in children. However, pharmacodynamic 
exposure studies have been conducted in murine models of invasive candidiasis and 
demonstrated that posaconazole efficacy is maximised with an unbound AUC24/MIC >20–
25 [192]. In one adult study, 67 patients with refractory invasive aspergillosis received 
posaconazole and were evaluated for their clinical response to therapy [193]. An exposure-
response relationship was defined, where 80 % of patients in the lowest mean plasma 
concentration quartile (< 0.13 μg/mL) experienced treatment failure as compared with 30 % 
of patients with steady-state posaconazole concentrations ≥1.25 μg/mL [193]. Further 
research is needed to determine if this exposure-response relationship exists in children.
4.4 Therapeutic Drug Monitoring
Therapeutic drug monitoring is rarely performed for fluconazole, largely owing to its 
relatively low pharmacokinetic variability and the lack of studies establishing a correlation 
between fluconazole concentrations and clinical outcomes [76, 77, 129]. If therapeutic drug 
monitoring for fluconazole is conducted, its extended half-life suggests that the timing of the 
sample does not influence the measured concentration once steady state has been reached 
[76]. A target AUC24 >400 mg·h/L is recommended to achieve an AUC/MIC > 25 for 
Candida species with an MIC at which 90 % of bacteria are inhibited (MIC90)of 8 μg/mL 
[194–196].
Numerous itraconazole pharmacodynamic studies have demonstrated strong links between 
drug concentrations and clinical efficacy for adult patients with superficial and invasive 
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fungal infections [134, 197–200]. Three studies have thus far investigated the utility of 
itraconazole therapeutic drug monitoring [197, 199, 201]. In a rabbit model of invasive 
pulmonary aspergillosis, Berenguer et al. [197] reported a strong inverse correlation between 
itraconazole plasma concentrations and Aspergillus fumigatus tissue density. Moreover, 
plasma concentrations <6 μg/mL resulted in a considerable loss of in vivo antifungal activity. 
This parallels reports from a study of 21 adults with invasive aspergillosis in which the mean 
itraconazole trough measured among patients who responded to therapy was 6.5 μg/mL, as 
compared with 4.2 μg/mL among those who did not respond to therapy [199]. In another 
study, itraconazole trough concentrations > 1 μg/mL were associated with therapeutic 
success among all HIV-infected adult patients who received treatment for cryptococcal 
meningitis [201]. In aggregate, these findings suggest that itraconazole therapeutic drug 
monitoring should be considered for immunocompromised patients and that trough 
concentrations > 1 μg/mL should be targeted.
Therapeutic drug monitoring for voriconazole is recommended for children with invasive 
fungal infections owing to high inter-individual variability and the lack of a well-defined 
dose-exposure relationship [202]. In several case series and case reports, voriconazole 
plasma concentrations were often reported to be subtherapeutic despite successive dose 
increases [154, 176]. Conversely, other children had dramatic increases in their measured 
voriconazole concentrations following small dose increases [154]. In a previously mentioned 
study conducted among 30 children with immunosuppressive conditions, plasma 
concentrations were found to vary widely and 73 % of the children required a dose 
adjustment [191]. The authors also reported that elevated trough concentrations (≥5.5 
μg/mL) were associated with dermatological and neurological adverse events, although a 
similar relationship was not demonstrated for hepatotoxicity [191]. Similarly, Neely et al. 
[155] reported that the risk of hepatotoxicity was not significantly associated with 
voriconazole dose, AUC, mean plasma concentration, Cmax or minimum plasma 
concentration. In aggregate, these findings suggest that target voriconazole trough 
concentrations should be> 1 μg/mL to maximise therapeutic effectiveness and<5.5 μg/mL to 
minimise the development of toxicity in children.
Several studies have reported a link between higher steady-state and trough posaconazole 
concentrations and improved clinical outcomes [193, 203]. Less than one in four adults who 
received posaconazole as salvage therapy for the treatment of invasive aspergillosis 
responded to therapy when their mean plasma concentration was < 0.15 μg/mL [193]. In 
contrast, three of four patients with a mean posaconazole concentration ≥1.25 μg/mL 
responded to therapy [193]. The optimal steady-state, peak or trough posaconazole target is 
unclear; however, Andes et al. [143] suggested that a steady-state plasma concentration of at 
least 0.5–1.5 μg/mL may be a reasonable target for patients with invasive fungal infections. 
Limited data suggest that there is not an association between elevated posaconazole plasma 
concentrations and toxicity [170]. In clinical trials, posaconazole was generally well-
tolerated and associated with fewer adverse drug–drug interactions than other members of 
the triazole family [204, 205].
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4.5 Drug Resistance
A major complicating factor in the use of fluconazole is the emergence of resistant fungal 
organisms. Multiple epidemiological studies have demonstrated that increased fluconazole 
use, both as a therapeutic and as a prophylactic, is associated with increased rates of non-
albicans Candida bloodstream infections [206, 207]. Additionally, several reports have 
suggested that the annual incidence of fluconazole-resistant oropharyngeal candidiasis in 
patients with AIDS has risen to approximately 5–10 % [208, 209]. Two randomised 
controlled trials evaluated prophylactic posaconazole versus fluconazole or itraconazole for 
immunocompromised patients at risk for invasive fungal disease and reported an increase in 
the frequency of fluconazoleresistant C. albicans during long-term prophylaxis but not in 
those who received posaconazole or itraconazole [210]. This differential resistance pattern 
among the triazoles may be attributable to a single point mutation in the gene that encodes 
the triazole-target lanosterol 14-α-demethylase (ERG11), which has been shown to confer 
fluconazole resistance [211]. In contrast, multiple mutations are required to affect 
posaconazole and itraconazole susceptibility [121]. Molecular dynamic studies have 
demonstrated that the long side chain present on posaconazole and itraconazole stabilises the 
binding affinity of these agents to regions surrounding the haeme cofactor CYP51 [212]. 
Consequently, more mutations are required to destabilise the long side chains of 
posaconazole and itraconazole, which are necessary to confer resistance to Candida species 
[212]. In the last decade, Aspergillus resistance to the triazole class has increased [213]. A 
point mutation in the CYP51A gene has been associated with posaconazole and itraconazole 
A. fumigatus resistance [214]. Additionally, a recent study from The Netherlands evaluated 
A. fumigatus isolates obtained from eight university hospitals and identified a new 
CYP51A-mediated voriconazole resistance mechanism in 21 isolates obtained from 15 
patients [215]. Eight patients were diagnosed with voriconazole-resistant invasive 
aspergillosis. At 12 weeks after isolation of the highly resistant A. fumigatus strain, four of 
eight (50 %) patients had died and two (25 %) had persisting infections. All of the patients 
who died had received primary therapy with voriconazole, whereas three of three (100 %) 
patients with invasive aspergillosis who received initial treatment with liposomal 
amphotericin B were alive at 12 weeks. Perhaps most concerning, the authors recovered 
these highly resistant strains from the air of the hospital paediatric ward as well as the 
patients’ homes and backyards [215]. As voriconazole yields response rates 15–20 % higher 
than non-triazole-containing regimens, it is currently the first-line antifungal agent for 
invasive aspergillosis, although monitoring for the spread of these highly resistant strains 
must be undertaken to ensure that changes in antifungal selection are guided by local 
epidemiology [216, 217].
4.6 Clinical Recommendations and Prospects for Future Research
The triazoles display time-dependent, concentration-independent fungistatic activity in mice, 
although further study is needed to assess whether a clinical relationship between adult 
pharmacodynamic targets (e.g. AUC/MIC >25) and clinical outcomes can be defined for 
children [24]. Based on limited in vitro and clinical data, fungicidal agents may be 
preferable to fungistatic drugs when treating invasive fungal infections in severely 
immunocompromised patients [202]. However, definitive randomised trials are needed to 
answer this question. There is also a pressing need to evaluate the efficacy of fluconazole 
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loading doses in children [188]. Lastly, very few studies have examined the 
pharmacokinetics of triazole-based combination therapies [218, 219]. In vitro studies have 
demonstrated that the combination of posaconazole and the echinocandin caspofungin 
exhibit synergistic antifungal activity against Zygomycetes [218]. Clinically, synergistic 
effects have also been described among adult patients treated concurrently with voriconazole 
and anidulafungin [219]. Further research is needed to define the pharmacokinetics and 
pharmacodynamics of triazole-based combination antifungal therapies in children, as no 
such studies currently exist.
5 Echinocandins
The first prospective trials to evaluate the echinocandins in children began in the early 2000s 
and since that time there has been a substantial increase in their use [27, 28, 220]. This is 
likely a consequence of their comparable efficacy and improved side effect profile when 
compared with other systemic antifungal agents [220]. These drugs exert their antifungal 
effects by inhibiting the ß-(1,3)-D-glucan synthase complex, which disrupts cell membrane 
permeability. The favourable side effect profile of the echinocandins is attributed to the 
absence of a mammalian ortholog of the glucan synthase complex and limited interaction 
with phase I/II metabolic enzymes [221].
Three echinocandin agents are approved for the treatment of invasive fungal infections in 
adults, including caspofungin, micafungin and anidulafungin. More recently, caspofungin 
and micafungin were approved for use in children [222, 223]. The echinocandins feature 
fungicidal activity against many Candida species and fungistatic activity against Aspergillus 
[224]. Additionally, the echi-nocandins have been used to successfully treat triazole-resistant 
Candida strains and have been reported to feature antifungal activity against biofilms [225, 
226]. These agents display similar clinical efficacy for a broad spectrum of invasive yeasts 
and moulds, are highly protein bound (97–99 %), are widely distributed (with the exception 
of the CSF and urine), and are well-tolerated. Despite these pharmacokinetic and 
pharmacodynamic similarities, age-specific metabolic differences influence dosing 
requirements for young children. The echinocandins are only available for parenteral 
administration, although they feature long half-lives and may be dosed once per day [221].
5.1 Pharmacokinetics and Pharmacodynamics
As large lipopeptides, the echinocandins exhibit poor oral bioavailability and must be 
administered parenterally [224]. The echinocandins exhibit linear pharmacokinetic profiles 
post-infusion and are slowly eliminated in the bile and faeces with varying degrees of 
degradation products found in the urine. Distribution occurs to most tissues with the 
exception of the CSF and the urine [224]. The activity of the echinocandins is attributed to 
concentration-dependent (e.g. AUC/MIC or Cmax/MIC) rather than time-dependent killing 
against Candida species [221]. Despite glycan synthase expression in other clinical 
opportunistic yeasts and moulds, echinocandins are not active against Zygomycetes, 
Fusarium species or Scedosporium species. Additionally, they are inactive against 
Trichosporon species due to the production of 1,6-D-glucan linkages [221]. None of the 
echinocandins are robust substrates for the CYP family or P-gp system, nor do they require 
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dosing adjustments in the setting of renal insufficiency [187]. While the echinocandins share 
many similarities in their pharmacokinetic and pharmacodynamic profiles, differences do 
exist. Caspofungin is subject to hydrolysis or N-acetylation, whereas micafungin is 
metabolised by catechol-O-methyltransferase and anidulafungin is chemically degraded 
[11].
For caspofungin, true pharmacokinetic steady state is estimated to require 2–3 weeks of 
dosing, although the majority of accumulation will occur within the first few days of 
administration [27]. After initial administration, caspofungin distributes to the kidney, lung, 
spleen and liver, with 35 % of the total dose residing hepatically at 24 h post-infusion [227]. 
A weight-based dosing regimen of caspofungin in children 2–11 years and two adolescents 
was found to be inadequate, leading to a significantly lower AUC24 and half-life than in 
adults receiving 50 mg/day [27]. However, using a body surface area (mg/m2) dosing 
regimen generated very similar AUC24 values when compared with adults after multiple 
doses (i.e. steady state). For both children and adolescents, dosing scaled to body surface 
area effectively controls for the variation in caspofungin clearance across the paediatric age 
range. However, it is not possible to achieve an identical AUC24, peak and trough profile to 
that of adults as the half-life of caspofungin is 30–40 % shorter in children. This may be 
driven by higher intrinsic transporter expression, increased blood flow and/or relative liver 
size [28].
Similar to caspofungin, the pharmacokinetic profile of micafungin is influenced by age [31, 
228]. Children ≤8 years of age exhibit higher micafungin clearance (up to 150 %), have an 
increased volume of distribution at steady state, and significantly shorter half-life than older 
children [28]. These findings were corroborated in a recent analysis of paediatric patients 
from a double-blind, randomised, multinational non-inferiority trial [228]. Micafungin and 
caspofungin exhibit similar Cmax and half-life profiles in children.
Compared to the FDA-approved echinocandins, relatively little is known about 
anidulafungin. From the few studies of anidulafungin in children, there are some notable 
differences in comparison with caspofungin and micafungin. Anidulafungin has a lower 
capacity for protein binding, a larger volume of distribution and a longer half-life [229]. 
Additionally, a dose-escalation study in children (2–11 years of age) and adolescents (12–17 
years of age) found that dosing by weight generated similar pharmacokinetic parameters to 
those in adults [229]. Additionally, anidulafungin rapidly reaches steady-state concentrations 
(after two doses) as compared with the other echinocandins [11].
The echinocandins exhibit a concentration-dependent post-antifungal effect, which appears 
to be inversely related to the duration of exposure [223]. This seems to be a corollary to the 
‘paradoxical effect’ where Candida species survive and continue to grow when exposed to 
high echinocandin concentrations. However, this has been demonstrated in vitro and the 
clinical relevance is not yet known [230, 231].
5.2 Intra- and Inter-Individual Variability
For the two FDA-approved echinocandins, the main source of pharmacokinetic variability in 
children is their decreasing clearance with increasing age [221]. Additionally, the underlying 
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disease status of the patient and concomitant medications also contribute to inter- and intra-
individual variability. Relatively small sample sizes in published paediatric studies make it 
difficult to assess differences in treatment outcomes by age, sex and race/ethnicity [232].
5.3 Dosing Optimisation
Current paediatric indications and dosing recommendations for the FDA-approved 
echinocandins are listed in Table 1. The echinocandins do not require dosing adjustments for 
patients with renal failure. However, in patients with severely compromised hepatic function 
a decrease in dosage is recommended for caspofungin and may be considered for 
micafungin [187, 221].
Micafungin has recently been approved for the treatment of candidaemia and antifungal 
prophylaxis in children ≥4 months of age [222]. For the treatment of oesophageal 
candidiasis among patients <30 kg, 3 mg/kg (2.5 mg/kg if < 30 kg) with a daily maximum of 
150 mg is recommended. For other sites (not including the CNS) of infection, 2 mg/kg with 
a maximum daily dose of 100 mg is recommended. This latest recommendation parallels 
experience from previous studies that used weight-based dosing and similar amounts of 
micafungin [221, 233]. However, the recommended dose for non-oesophageal candidaemia 
(2 mg/kg) results in a 25 % lower Cmax and 50 % lower AUC for children < 5 years of age 
[234]. However, Undre et al. [234] caution that no children failed therapy due to a lack of 
efficacy and their sample size prohibited their ability to establish definitive paediatric dosing 
recommendations. Additionally, the authors hypothesised that younger children are likely to 
have a higher free fraction of micafungin due to developmental changes in protein binding 
[235]. In an open-label study assessing micafungin safety and pharmacokinetics, mica-
fungin was well-tolerated in infants with suspected invasive CNS candidiasis who received 
up to 10 mg/kg/day [236, 237]. This finding is in agreement with 2009 IDSA guidelines, 
which recommend paediatric micafungin doses of 2–4 mg/kg/day [187].
As with micafungin, early studies of caspofungin indicated that children and adolescents 
require higher doses than adults [27]. Dosing caspofungin based on body surface area rather 
than weight led to consistent achievement of plasma concentrations that correlated with 
efficacy in adults [187]. Unlike the other echinocandins, the pharmacokinetics of 
caspofungin necessitate a loading dose. FDA dosing recommendations for children ≥3 
months are based on body surface area. The loading dose is 70 mg/m2 on day 1 with a 
maintenance dose of 50 mg/m2 up to a maximum of 70 mg/m2 if required.
Anidulafungin is not approved for use in paediatric patients in the USA or Europe and 
limited data exist regarding its use in children. However, like micafungin and caspofungin, 
its safety and efficacy profiles appear promising [238, 239]. Dosing by weight has led to 
similar pharmacokinetic profiles as found in adults and, in contrast to the other 
echinocandins, anidulafungin clearance does not depend on age [223].
Small sample sizes among paediatric studies have made assignation of echinocandin-specific 
adverse drug reactions imprecise. Many of the reported side effects are consistent with adult 
data, including gastrointestinal disturbances (vomiting, diarrhoea, fever, nausea, abdominal 
pain) and transaminase elevation. Discontinuation due to these side effects is infrequent 
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(3.8 % in a substudy of micafungin use in paediatric patients < 16 years of age) relative to 
other classes of antifungals and infusion-related hypersensitivity reactions are rare [233].
5.4 Therapeutic Drug Monitoring
At present, therapeutic drug monitoring is not recommended for the echinocandins due to a 
lack of evidence that suggests that routine plasma concentration monitoring provides utility 
in clinical practice [202, 240]. Nonetheless, in a case of neonatal meningitis, therapeutic 
monitoring of caspofungin concentrations in the CSF was found to be useful in establishing 
caspofungin concentrations that were sufficient to sterilise the CSF [241]. Additionally, 
monitoring may be considered when cyclosporine is coadministered, which has been 
reported to increase caspofungin and anidulafungin plasma concentrations due to diminished 
hepatic uptake [242]. Conversely, cyclosporine concentrations may become elevated when 
administered with micafungin. A similar pattern has been reported for sirolimus and 
nifedipine, which also occurs as a consequence of mild CYP3A inhibition [243]. Tacrolimus 
concentrations may be decreased with the concurrent use of caspofungin; however, this has 
not been reported to cause toxicity [244]. Agents known to induce hepatic metabolism, such 
as rifampin (rifampicin), can lead to significant decreases in caspofungin plasma 
concentrations [242].
5.5 Drug Resistance
Echinocandin resistance is rare and has been reported in <1.2 % of Candida species isolated 
in a recent global surveillance study [245, 246]. However, evidence of clinically resistant 
Candida with MICs within the susceptible and intermediate breakpoints has prompted a 
reassessment of echinocandin susceptibilities [247]. Although multiple potential 
mechanisms of resistance have been demonstrated in vitro, clinically relevant echinocandin 
resistance for Candida species is driven primarily by ‘hot spot’ mutations in the β-1,3-D-
glucan synthase (encoded by the fks1/fks2 genes) target enzyme [248, 249]. The former 
breakpoint MIC of ≤2 deemed as ‘susceptible’ for all Candida species and the echinocandin 
class has been revised [247]. Currently, MICs >0.5 μg/mL are considered resistant for 
anidulafungin, caspofungin and micafungin against C. albicans, C. tropicalis and C. krusei 
and >0.4 μg/mL for C. parapsilosis. C. glabrata resistance may be on the rise and is defined 
at values >0.12 μg/mL for micafungin and > 0.25 μg/mL for anidulafungin and caspofungin. 
Clinical breakpoints have not been defined for Aspergillus species [245]. Cross-resistance 
with the polyenes or triazoles has not been reported. Rather, the echinocandins are 
considered first-line agents for the treatment of fluconazole-resistant strains of Candida 
[221]. Resistance to one echinocandin can generally be interpreted as resistance to the entire 
class [246, 247].
5.6 Clinical Recommendations and Prospects for Future Research
The use of echinocandins in paediatric patients has substantially increased over the last 5 
years [220, 232]. The echinocandins offer comparable efficacy, an improved safety profile, 
and advantages in treating resistant fungal infections and refractory biofilms. However, the 
evolving story of drug-drug interactions and uncertainties regarding pharmacodynamic 
exposure-response relationships are two key areas where there are still many unanswered 
questions. A recent survey of prescribing practices among Japanese physicians in paediatric 
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patients with invasive fungal infections found that physicians were more likely to use 
antifungals based on perceptions of potency rather than on safety. Micafungin was the most 
frequently prescribed [250]. More research is needed to ensure that paediatric echinocandin 
dosing regimens are optimised for therapeutic effectiveness without compromising patient 
safety or tolerability.
6 Summary and Conclusions
The introduction of several new systemic antifungal agents in the last two decades has 
expanded our therapeutic arsenal for the treatment of invasive fungal infections. However, 
with these new agents comes a pressing need to understand their pharmacokinetic properties, 
clinical effects and associated toxicities.
The pharmacokinetic and pharmacodynamic characteristics of systemic antifungal agents 
have been well-studied in adults; however, paediatric-specific data are limited. Extensive in 
vitro and animal model studies have demonstrated strong relationships linking antifungal 
exposure to treatment efficacy. Our understanding of these principles is increasing and has 
highlighted the utility of therapeutic drug monitoring for flucytosine, itraconazole, 
voriconazole and posaconazole. However, further research is needed to define the 
pharmacokinetics, pharmacodynamics and clinical utility of combination antifungal 
therapies in children.
From all of the studies discussed in this review, it must be concluded that—in the absence of 
data—antifungal pharmacokinetics in children cannot be assumed to mirror adult 
pharmacokinetic parameters. However, antifungal pharmacodynamic targets are remarkably 
similar among all age groups, different drugs within the same class, and even across species. 
These pharmacodynamic targets provide clinicians the opportunity to predict treatment 
efficacy.
Acknowledgments
None.
Funding This work was supported by grants from the US National Institute of Allergy and Infectious Diseases 
[Grant Number U01A1082482] (to KA) and the Centres for Disease Control Prevention [U18-IP000303-01] (to CS, 
KA).
References
1. Blyth CC, Palasanthiran P, O’Brien TA. Antifungal therapy in children with invasive fungal 
infections: a systematic review. Pediatrics. 2007; 119(4):772–84. [PubMed: 17403849] 
2. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in 
very low birth weight neonates: the experience of the NICHD Neonatal Research Network. 
Pediatrics. 2002; 110(2 Pt 1):285–91. [PubMed: 12165580] 
3. Benjamin DK, DeLong E, Cotten CM, Garges HP, Steinbach WJ, Clark RH. Mortality following 
blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but 
not Gram-positive bacteremia. J Perinatol. 2004; 24(3):175–80. [PubMed: 14985775] 
4. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al. Risk factors for 
candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis 
Survey Study Group. Pediatr Infect Dis J. 2000; 19(4):319–24. [PubMed: 10783022] 
Stockmann et al. Page 22
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus 
infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis J. 1993; 12(8):673–82. 
[PubMed: 8414781] 
6. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. 
Clin Infect Dis. 2001; 32(3):358–66. [PubMed: 11170942] 
7. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal 
agents. Clin Infect Dis. 2006; 43(Suppl 1):S28–39.
8. Steinbach WJ. Antifungal agents in children. Pediatric Clin N Am. 2005; 52(3):895–915. viii.
9. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, et al. Deletion of the 
Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, 
and antifungal susceptibility. Antimicrob Agents Chemother. 1995; 39(12):2708–17. [PubMed: 
8593007] 
10. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. 
Chemotherapy. 1975; 21(3–4):113–30. [PubMed: 1098864] 
11. Denning DW. Echinocandin antifungal drugs. Lancet. 2003; 362(9390):1142–51. [PubMed: 
14550704] 
12. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a 
neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000; 44(4):
938–42. [PubMed: 10722494] 
13. Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, Kaw P, et al. Pharmacodynamics of fluconazole 
in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998; 42(5):1105–9. 
[PubMed: 9593135] 
14. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of 
fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents 
Chemother. 1999; 43(9):2116–20. [PubMed: 10471550] 
15. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse 
disseminated-candidiasis model. Antimicrob Agents Chemother. 2001; 45(3):922–6. [PubMed: 
11181381] 
16. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH. A comparative study of 
the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus 
fumigatus and Candida albicans. J Antimicrob Chemother. 2004; 53(2):386–9. [PubMed: 
14729762] 
17. Chryssanthou E, Sjolin J. Post-antifungal effect of amphotericin B and voriconazole against 
Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: 
dependence on exposure time and drug concentration. J Antimicrob Chemother. 2004; 54(5):940–
3. [PubMed: 15471994] 
18. Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo 
pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. 
Antimicrob Agents Chemother. 2008; 52(2):539–50. [PubMed: 18070979] 
19. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. In vivo pharmacodynamic target 
investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine 
candidiasis model. Antimicrob Agents Chemother. 2008; 52(10):3497–503. [PubMed: 18625768] 
20. Andes D, Lepak A, Nett J, Lincoln L, Marchillo K. In vivo fluconazole pharmacodynamics and 
resistance development in a previously susceptible Candida albicans population examined by 
microbiologic and transcriptional profiling. Antimicrob Agents Chemother. 2006; 50(7):2384–94. 
[PubMed: 16801416] 
21. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics 
of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 
2003; 47(10):3165–9. [PubMed: 14506026] 
22. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of 
mice and men. Clin Infect Dis. 1998; 26(1):1–10. quiz 1–2. [PubMed: 9455502] 
23. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. 
Pediatr Infect Dis J. 1996; 15(3):255–9. [PubMed: 8852915] 
Stockmann et al. Page 23
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob 
Agents Chemother. 2003; 47(4):1179–86. [PubMed: 12654644] 
2. Wiederhold NP, Herrera LA. Caspofungin for the treatment of immunocompromised and severely ill 
children and neonates with invasive fungal infections. Clin Med Insights Pediatr. 2012; 6:19–31. 
[PubMed: 23641163] 
26. Katragkou A, Roilides E. Best practice in treating infants and children with proven, probable or 
suspected invasive fungal infections. Curr Opin Infect Dis. 2011; 24(3):225–9. [PubMed: 
21455060] 
27. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, et al. Pharmacokinetics, 
safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 
2005; 49(11):4536–45. [PubMed: 16251293] 
28. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, et al. Safety, tolerability, and 
pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob 
Agents Chemother. 2005; 49(8):3317–24. [PubMed: 16048942] 
29. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin 
versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients 
undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004; 39(10):1407–16. 
[PubMed: 15546073] 
30. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin 
versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever 
and neutropenia. N Engl J Med. 2004; 351(14):1391–402. [PubMed: 15459300] 
31. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, et al. Population 
pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. 
Antimicrob Agents Chemother. 2007; 51(10):3714–9. [PubMed: 17638696] 
32. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology–drug disposition, action, and therapy in infants and children. N 
Engl J Med. 2003; 349(12):1157–67. [PubMed: 13679531] 
33. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol 
Infect. 2010; 16(9):1343–53. [PubMed: 20678177] 
34. Walsh TJ. Management of immunocompromised patients with evidence of an invasive mycosis. 
Hematol Oncol Clin North Am. 1993; 7(5):1003–26. [PubMed: 8226563] 
35. Sarosi GA, Amphotericin B. Still the ‘gold standard’ for antifungal therapy. Postgrad Med. 1990; 
88(1):151–2. 5–61, 65–6. [PubMed: 2195479] 
36. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect 
Dis. 1990; 12(2):308–29. [PubMed: 2184499] 
37. Cohen-Wolkowiez M, Moran C, Benjamin DK Jr, Smith PB. Pediatric antifungal agents. Curr Opin 
Infect Dis. 2009; 22(6):553–8. [PubMed: 19741525] 
38. Je, B. Antifungal agents. In: Hardman, GELL., editor. Goodman and Gilman’s the pharmacological 
basis of therapeutics. 10th. New York: McGraw-Hill; 2001. p. 1295-312.
39. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002; 
49(Suppl 1):31–6.
40. Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, et al. 
Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin 
B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006; 57(6):1153–60. 
[PubMed: 16627591] 
41. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents 
Chemother. 1978; 13(2):271–6. [PubMed: 646348] 
42. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of 
treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990; 
116(5):791–7. [PubMed: 2329429] 
43. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents 
Chemother. 1989; 33(11):1989–93. [PubMed: 2610508] 
Stockmann et al. Page 24
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
44. Raasch, RH., Hopfer, RL. Antifungal agents. In: Munson, PL.Mueller, RA., Breese, GR., editors. 
Principles of pharmacology: basic concepts and clinical applications, revised reprint. New York: 
Chapman and Hall; 1996. p. 1401-11.
45. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for 
adverse events related to infusion of amphotericin B. Clin Infect Dis. 1995; 20(4):755–61. 
[PubMed: 7795069] 
46. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of 
nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin 
Infect Dis. 1999; 29(6):1402–7. [PubMed: 10585786] 
47. Chabot GG, Pazdur R, Valeriote FA, Baker LH. Pharmacokinetics and toxicity of continuous 
infusion amphotericin B in cancer patients. J Pharm Sci. 1989; 78(4):307–10. [PubMed: 2724094] 
48. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine 
A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. 
Swiss Med Wkly. 2002; 132(23–24):316–20. [PubMed: 12362282] 
49. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B 
deoxycholate: an open-label observational study. Clin Infect Dis. 2003; 36(8):943–51. [PubMed: 
12684904] 
50. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study 
involving high-risk haematology patients. J Antimicrob Chemother. 2004; 54(4):803–8. [PubMed: 
15308606] 
51. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused 
over 4 or 24 hours: randomised controlled trial. BMJ. 2001; 322(7286):579–82. [PubMed: 
11238151] 
52. Bekersky IFR, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics 
of bound versus unbound amphotericin B after administration of intravenous liposomal 
amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 
2003; 46:834–40.
53. Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP. In vitro pharmacodynamics of rapid 
versus continuous infusion of amphotericin B deoxycholate against Candida species in the 
presence of human serum albumin. J Antimicrob Chemother. 2006; 57(2):288–93. [PubMed: 
16387749] 
54. Janoff ASPW, Saleton SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular 
rationale for the attenuation of amphotericin B-related toxicities. J Liposome Res. 1993; 3:451–72.
55. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP. Tissue distribution of amphotericin B lipid 
complex in laboratory animals. J Pharm Pharmacol. 1991; 43(12):831–5. [PubMed: 1687580] 
56. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B 
lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother. 
1991; 35(4):615–21. [PubMed: 2069367] 
57. Lee, J., Allende, M., Dollenberg, H., Garrett, K., Berenguer, J., Francesconi, A., et al. Interscience 
conference on antimicrobial agents and chemotherapy (ICAAC), 1992. Anaheim: American 
Society for Microbiology; 1992. Reticuloendothelial loading with ampho-tericin B lipid complex 
(ABLC)—a novel pharmacodynamic approach to treatment of experimental hepatosplenic 
candidiasis (HSC) [abstract no. 172]; p. 139
58. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, et al. Comparative 
safety, tolerance, and pharma-cokinetics of amphotericin B lipid complex and amphotericin B 
desoxycholate in healthy male volunteers. J Infect Dis. 1991; 164(2):418–21. [PubMed: 1856491] 
59. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of 
amphotericin B after administration of a novel colloidal delivery system, ABCD, and a 
conventional formulation to rats. Antimicrob Agents Chemother. 1991; 35(6):1208–13. [PubMed: 
1929263] 
60. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS. Relationship of pharmacokinetics and 
drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. 
Antimicrob Agents Chemother. 1992; 36(2):299–307. [PubMed: 1605595] 
Stockmann et al. Page 25
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
61. Fielding, RM., Porter, J., Jekot, J., Guo, LSS. Annual Meeting of the American Society for 
Microbiology (ASM), 1991. Dallas: American Society for Microbiology; 1991. Altered tissue 
distribution results in the reduced toxicity of amphotericin B colloidal dispersion [abstract no. 
A77]; p. 13
62. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal 
dispersion in the treatment of invasive mycoses. Clin Infect Dis. 1995; 21(5):1145–53. [PubMed: 
8589134] 
63. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a 
liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991; 
28(Suppl B):49–61. [PubMed: 1778892] 
64. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, et al. Pharmacokinetics and 
safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. 
Antimicrob Agents Chemother. 1994; 38(4):713–8. [PubMed: 8031034] 
65. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of 
AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993; 
3:429–50.
66. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes 
(AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J 
Antimicrob Chemother. 1991; 28(suppl B):73–82.
67. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and 
pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with 
Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob 
Agents Chemother. 2001; 45(12):3487–96. [PubMed: 11709329] 
68. Hong Y, Shaw PJ, Nath CE, Yadav SP, Stephen KR, Earl JW, et al. Population pharmacokinetics of 
liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents 
Chemother. 2006; 50(3):935–42. [PubMed: 16495254] 
69. Starke JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants 
and children. J Infect Dis. 1987; 155(4):766–74. [PubMed: 3819480] 
70. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population 
pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 
2005; 49(12):5092–8. [PubMed: 16304177] 
71. Luna B, Drew RH, Perfect JR. Agents for treatment of invasive fungal infections. Otolaryngol Clin 
North Am. 2000; 33(2):277–99. [PubMed: 10736404] 
72. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic 
activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a 
neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 
2006; 50(2):469–73. [PubMed: 16436698] 
73. Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of 
conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss 
Med Wkly. 2002; 132(31–32):455–8. [PubMed: 12457304] 
74. Maharom P, Thamlikitkul V. Implementation of clinical practice policy on the continuous 
intravenous administration of amphotericin B deoxycholate. J Med Assoc Thai. 2006; 89(Suppl 
5):S118–24.
75. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal 
amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-
loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007; 44(10):1289–
97. [PubMed: 17443465] 
76. Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic 
antifungal therapy. J Antimicrob Chemother. 1997; 40(6):753–64. [PubMed: 9462426] 
77. Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical 
pharmacology and therapeutic applications. Drugs. 1992; 44(1):9–35. [PubMed: 1379913] 
78. Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial 
Chemotherapy Working Party. Lancet. 1991; 337(8757):1577–1580. [PubMed: 1675717] 
Stockmann et al. Page 26
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
79. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited: reassessment of toxicity. Am J Med. 
1990; 88(5N):22N–7N.
80. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical 
outcome? J Infect. 1994; 28(Suppl 1):17–24. [PubMed: 8077687] 
81. Karlsson MO, Sheiner LB. The importance of modeling inter-occasion variability in population 
pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993; 21(6):735–50. [PubMed: 8138894] 
82. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin 
resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006; 
42(7):938–44. [PubMed: 16511756] 
83. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, et al. 
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, 
and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 
2012; 50(6):2040–6. [PubMed: 22461672] 
84. Steinbach WJ, Perfect JR, Schell WA, Walsh TJ, Benjamin DK Jr. In vitro analyses, animal 
models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents 
Chemother. 2004; 48(9):3217–25. [PubMed: 15328076] 
85. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol 
biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother. 
2003; 47(8):2404–12. [PubMed: 12878497] 
86. LA Vincent BM, Scherz-Shouval R, Whitesell L, Lindquist S. Fitness trade-offs restrict the 
evolution of resistance to amphotericin B. PLoS Biol. 2013; 11(10):e1001692. [PubMed: 
24204207] 
87. Lewis RE, Wiederhold NP. The solubility ceiling: a rationale for continuous infusion amphotericin 
B therapy? Clin Infect Dis. 2003; 37(6):871–2. [PubMed: 12955666] 
88. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical 
efficacy and toxicities. Clin Infect Dis. 1998; 27(3):603–18. [PubMed: 9770163] 
89. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 
2013; 73(9):919–34. [PubMed: 23729001] 
90. Polak A, Grenson M. Evidence for a common transport system for cytosine, adenine and 
hypoxanthine in Saccharomyces cerevisiae and Candida albicans. Eur J Biochem. 1973; 32(2):
276–82. [PubMed: 4569075] 
91. Waldorf AR, Polak A. Mechanisms of action of 5-fluorocyto-sine. Antimicrob Agents Chemother. 
1983; 23(1):79–85. [PubMed: 6338821] 
92. Diasio RB, Bennett JE, Myers CE. Mode of action of 5-flu-orocytosine. Biochem Pharmacol. 
1978; 27(5):703–7. [PubMed: 350227] 
93. Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal 
function. Clin Pharmacol Ther. 1978; 24(3):333–42. [PubMed: 688726] 
94. Francis P, Walsh TJ. Evolving role of flucytosine in immuno-compromised patients: new insights 
into safety, pharmacoki-netics, and antifungal therapy. Clin Infect Dis. 1992; 15(6):1003–18. 
[PubMed: 1457631] 
95. Bennet JE. Flucytosine. Ann Intern Med. 1977; 86(3):319–21. [PubMed: 320931] 
96. Block ER, Bennett JE, Livoti LG, Klein WJ Jr, MacGregor RR, Henderson L. Flucytosine and 
amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. 
Ann Intern Med. 1974; 80(5):613–7. [PubMed: 4823813] 
97. Schonebeck J, Polak A, Fernex M, Scholer HJ. Pharmacokinetic studies on the oral antimycotic 
agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy. 
1973; 18(6):321–36. [PubMed: 4741211] 
98. Muther RS, Bennett WM. Peritoneal clearance of amphotericin B and 5-fluorocytosine. West J 
Med. 1980; 133(2):157–60. [PubMed: 7015695] 
99. Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resist 
Updat. 2005; 8(4):235–45. [PubMed: 16054422] 
100. Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and 
pharmacokinetic parameters. Chemotherapy. 2000; 46(2):86–94. [PubMed: 10671757] 
Stockmann et al. Page 27
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
101. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 
2,121 published cases. Rev Infect Dis. 1990; 12(6):1147–201. [PubMed: 2267490] 
102. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the 
disease in 98 patients. Medicine (Baltimore). 1970; 49(2):147–73. [PubMed: 4913991] 
103. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical 
indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000; 
46(2):171–9. [PubMed: 10933638] 
104. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother. 1991; 28(Suppl B):27–
38. [PubMed: 1778890] 
105. Utz JP, Tynes BS, Shadomy HJ, Duma RJ, Kannan MM, Mason KN. 5-Fluorocytosine in human 
cryptococcosis. Antimicrob Agents Chemother. 1968; 8:344–6. [PubMed: 5735379] 
106. Medoff G, Comfort M, Kobayashi GS. Synergistic action of amphotericin B and 5-fluorocytosine 
against yeast-like organisms. Proc Soc Exp Biol Med. 1971; 138(2):571–4. [PubMed: 5118468] 
107. Soltani M, Tobin CM, Bowker KE, Sunderland J, MacGowan AP, Lovering AM. Evidence of 
excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of 
serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents. 
2006; 28(6):574–7. [PubMed: 17085019] 
108. Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, et al. Optimization of the dosage of 
flucytosine in combination with amphotericin B for disseminated candidiasis: a 
pharmacodynamic rationale for reduced dosing. Antimicrob Agents Chemother. 2007; 51(10):
3760–2. [PubMed: 17682101] 
109. Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs. 2005; 6(2):
170–7.
110. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of 
amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987; 
83(2):236–42. [PubMed: 3303926] 
111. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm. 1988; 7(6):424–
38. [PubMed: 3042267] 
112. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc. 
1998; 73(12):1205–25. [PubMed: 9868423] 
113. Fasoli M, Kerridge D. Isolation and characterization of fluoropyrimidine-resistant mutants in two 
Candida species. Ann N Y Acad Sci. 1988; 544:260–3. [PubMed: 3063172] 
114. Polak A. 5-Fluorocytosine—current status with special references to mode of action and drug 
resistance. Contrib Microbiol Immunol. 1977; 4:158–67. [PubMed: 342192] 
115. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med. 
1980; 302(3):145–55. [PubMed: 6985703] 
116. Armstrong, D., Schmitt, HJ. Older drugs. In: Ryley, JF., editor. Chemotherapy for fungal diseases. 
Berlin: Springer; 1990. p. 439-54.
117. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011; 86(8):805–17. 
[PubMed: 21803962] 
118. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 
2003; 11(6):272–9. [PubMed: 12823944] 
119. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin 
Microbiol Rev. 1999; 12(1):40–79. [PubMed: 9880474] 
120. Chen SC, Sorrell TC. Antifungal agents. Med J Aust. 2007; 187(7):404–9. [PubMed: 17908006] 
121. Katragkou A, Tsikopoulou F, Roilides E, Zaoutis TE. Posaconazole: when and how? The 
clinician’s view. Mycoses. 2012; 55(2):110–22. [PubMed: 21762211] 
122. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of 
posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical 
isolates of zygomycetes. Antimicrob Agents Chemother. 2002; 46(5):1581–2. [PubMed: 
11959605] 
Stockmann et al. Page 28
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
123. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration 
into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. 
J Infect Dis. 1988; 157(1):178–80. [PubMed: 2826606] 
124. Brammer, KW., Tarbit, MH. A review of the pharmacokinetics of fluconazole (UK-49,858) in 
laboratory animals and man. In: Fromtling, RA., editor. Recent trends in the discovery, 
development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers SA; 
1987. p. 141-50.
125. Farrow, PR., Faulkner, JK., Brammer, KW. Symposium on Fluconazole: a Novel Advance in 
Therapy for Systemic Fungal Infections. Dorado: Puerto Rico; Oct 8–9. 1988 The 
pharmacokinetics of fluconazole [abstract no. 14-199]. 
126. Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of 
[14]fluconazole in humans. Drug Metab Dispos. 1991; 19(4):764–7. [PubMed: 1680653] 
127. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin 
Microbiol Infect Dis. 1994; 13(4):325–9. [PubMed: 8070441] 
128. Blum RA, D’Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, Gardner MJ, et al. Increased 
gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991; 
114(9):755–7. [PubMed: 2012358] 
129. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic 
properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990; 39(6):
877–916. [PubMed: 2196167] 
130. Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight 
infants during the first two weeks of life. Clin Pharmacol Ther. 1993; 54(3):269–77. [PubMed: 
8375121] 
131. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001; 61(Suppl 1):27–37.
132. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. 
Drugs. 2001; 61(Suppl 1):39–47. [PubMed: 11219549] 
133. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of 
itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997; 37(6):535–40. [PubMed: 
9208361] 
134. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. 
Clin Pharmacokinet. 1998; 35(6):461–73. [PubMed: 9884817] 
135. Groll AH, Wood L, Roden M, Mickiene D, Chiou CC, Townley E, et al. Safety, 
pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with 
oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002; 46(8):2554–63. [PubMed: 
12121932] 
136. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The 
clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989; 32(Suppl 1):67–87. 
[PubMed: 2561187] 
137. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics 
of itraconazole following oral administration to normal volunteers. Antimicrob Agents 
Chemother. 1988; 32(9):1310–3. [PubMed: 2848442] 
138. de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, et al. Repeated-dose 
pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents 
Chemother. 1998; 42(2):404–8. [PubMed: 9527794] 
139. Abdel-Rahman SM, Jacobs RF, Massarella J, Kauffman RE, Bradley JS, Kimko HC, et al. Single-
dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in 
infants, children, and adolescents. Antimicrob Agents Chemother. 2007; 51(8):2668–73. 
[PubMed: 17517842] 
140. Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics 
of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob 
Chemother. 1994; 34(2):247–52. [PubMed: 7814285] 
141. Prentice AG, Warnock DW, Johnson SA, Taylor PC, Oliver DA. Multiple dose pharmacokinetics 
of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid 
leukaemia. J Antimicrob Chemother. 1995; 36(4):657–63. [PubMed: 8591940] 
Stockmann et al. Page 29
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
142. Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, et al. 
Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the 
time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug 
Metab Dispos. 2008; 36(6):1097–101. [PubMed: 18339815] 
143. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and 
emerging indications. Antimicrob Agents Chemother. 2009; 53(1):24–34. [PubMed: 18955533] 
144. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of 
oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 
2002; 42(4):395–402. [PubMed: 11936564] 
145. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum 
triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003; 56(Suppl 1):10–6. 
[PubMed: 14616408] 
146. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics 
and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob 
Agents Chemother. 2002; 46(8):2546–53. [PubMed: 12121931] 
147. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the 
N-oxidation of voriconazole. Drug Metab Dispos. 2003; 31(5):540–7. [PubMed: 12695341] 
148. Service RF. Pharmacogenomics. Going from genome to pill. Science. 2005; 308(5730):1858–60. 
[PubMed: 15976283] 
149. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of 
voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012; 56(6):
3032–42. [PubMed: 22430956] 
150. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents 
Chemother. 2012; 56(1):526–31. [PubMed: 22064545] 
151. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of 
voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004; 75(6):587–
8. [PubMed: 15179414] 
152. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. 
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-
dose administration. Antimicrob Agents Chemother. 2004; 48(6):2166–72. [PubMed: 15155217] 
153. Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Voriconazole 
pharmacokinetics and safety in immunocompromised children compared to adult patients. 
Antimicrob Agents Chemother. 2010; 54(8):3225–32. [PubMed: 20547816] 
154. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis 
Child. 2008; 93(7):578–81. [PubMed: 18252755] 
155. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and 
pharmacodynamics in children. Clin Infect Dis. 2010; 50(1):27–36. [PubMed: 19951112] 
156. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug 
monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect 
Dis. 2008; 46(2):201–11. [PubMed: 18171251] 
157. Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole 
therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood 
Cancer. 2013; 60(1):82–7. [PubMed: 22887791] 
158. Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum 
triazole posaconazole: an overview. Br J Clin Pharmacol. 2010; 70(4):471–80. [PubMed: 
20840439] 
159. Moxafil® [package insert]. Whitehouse Station: Merck & Co., Inc.; 2013. 
160. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral 
posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or 
myelodysplastic syndrome. Pharmacotherapy. 2008; 28(10):1223–32. [PubMed: 18823218] 
161. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral 
posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents 
Chemother. 2003; 47(9):2788–95. [PubMed: 12936975] 
Stockmann et al. Page 30
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
162. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of 
posaconazole in fasted healthy subjects: comparison between three regimens and basis for 
clinical dosage recommendations. Clin Pharmacokinet. 2005; 44(2):211–20. [PubMed: 
15656699] 
163. Krishna G, Ma L, Martinho M, Preston RA, O’Mara E. A new solid oral tablet formulation of 
posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose 
pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012; 67(11):2725–
30. [PubMed: 22833639] 
164. Krishna G, Ma L, Martinho M, O’Mara E. Single-dose phase I study to evaluate the 
pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral 
suspension. Antimicrob Agents Chemother. 2012; 56(8):4196–201. [PubMed: 22615291] 
165. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on 
cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 
2004; 21(5):645–53. [PubMed: 15066665] 
166. Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. Maximal inhibition of intestinal first-pass 
metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for 
CYP3A4 cleared drugs. Curr Drug Metab. 2007; 8(7):685–93. [PubMed: 17979656] 
167. Conte JE Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary 
pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. 
Antimicrob Agents Chemother. 2009; 53(2):703–7. [PubMed: 19029316] 
168. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. 
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the 
glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004; 32(2):267–71. [PubMed: 
14744950] 
169. Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 
2007; 29(9):1862–86. [PubMed: 18035188] 
170. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma 
concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 
2007; 51(3):812–8. [PubMed: 17210771] 
171. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ. Safety and pharmacokinetics 
of fluconazole in children with neoplastic diseases. J Pediatr. 1992; 120(6):987–93. [PubMed: 
1593362] 
172. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and 
dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 
1989; 36(4):423–6. [PubMed: 2544431] 
173. Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Itraconazole, a P-glycoprotein 
and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-
inhibiting effect of aliskiren. J Clin Pharmacol. 2011; 51(3):359–67. [PubMed: 20400651] 
174. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, et al. Molecular and 
physical mechanisms of first-pass extraction. Drug Metab Dispos. 1999; 27(2):161–6. [PubMed: 
9929497] 
175. Bartell APA, Horn K, Postelnick M. Drug interactions involving antifungal drugs: time course 
and clinical significance. Curr Fungal Infect Rep. 2010; 4:103–10.
176. Doby EH, Benjamin DK Jr, Blaschke AJ, Ward RM, Pavia AT, Martin PL, et al. Therapeutic 
monitoring of voriconazole in children less than three years of age: a case report and summary of 
voriconazole concentrations for ten children. Pediatr Infect Dis J. 2012; 31(6):632–5. [PubMed: 
22301479] 
177. Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, et al. Pediatric invasive 
aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008; 
121(5):e1286–94. [PubMed: 18450871] 
178. Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, et al. Voriconazole plasma 
levels in children are highly variable. Eur J Clin Microbiol Infect Dis. 2011; 30(2):283–7. 
[PubMed: 20963460] 
Stockmann et al. Page 31
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
179. Shima H, Miharu M, Osumi T, Takahashi T, Shimada H. Differences in voriconazole trough 
plasma concentrations per oral dosages between children younger and older than 3 years of age. 
Pediatr Blood Cancer. 2010; 54(7):1050–2. [PubMed: 20146339] 
180. Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable 
plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation 
patients. Antimicrob Agents Chemother. 2013; 57(1):235–40. [PubMed: 23114771] 
181. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma 
concentration data from pediatric studies. Antimicrob Agents Chemother. 2009; 53(3):935–44. 
[PubMed: 19075073] 
182. Maples HD, Stowe CD, Saccente SL, Jacobs RF. Voriconazole serum concentrations in an infant 
treated for Trichosporon beigelii infection. Pediatr Infect Dis J. 2003; 22(11):1022–4. [PubMed: 
14628778] 
183. Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, et al. 
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. 
Antimicrob Agents Chemother. 2006; 50(6):1993–9. [PubMed: 16723557] 
184. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 
1989; 8(4):323–30. [PubMed: 2497012] 
185. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, et al. Safety, plasma 
concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis. 
1995; 172(2):599–602. [PubMed: 7622915] 
186. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for 
the treatment of candidiasis. Infectious Diseases Society of America. Clin infect Dis. 2000; 
30(4):662–78. [PubMed: 10770728] 
187. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical 
practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases 
Society of America. Clin Infect Dis. 2009; 48(5):503–35. [PubMed: 19191635] 
188. Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, et al. Fluconazole loading 
dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011; 30(5):375–8. [PubMed: 
21085048] 
189. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of 
MIC with outcome for Candida species tested against voriconazole: analysis and proposal for 
interpretive breakpoints. J Clin Microbiol. 2006; 44(3):819–26. [PubMed: 16517860] 
190. Food and Drug Administration. Briefing document for voriconazole. United States Food and Drug 
Administration; Washington DC: 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/
3792b2.htm Accessed 24 Nov 2013
191. Soler-Palacin P, Frick MA, Martin-Nalda A, Lanaspa M, Pou L, Rosello E, et al. Voriconazole 
drug monitoring in the management of invasive fungal infection in immunocompromised 
children: a prospective study. J Antimicrob Chemother. 2012; 67(3):700–6. [PubMed: 22190607] 
192. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, et al. Pharmacodynamics 
of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob 
Agents Chemother. 2004; 48(1):137–42. [PubMed: 14693531] 
193. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of 
invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of 
conventional therapy: an externally controlled trial. Clin Infect Dis. 2007; 44(1):2–12. [PubMed: 
17143808] 
194. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida 
revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006; 
19(2):435–47. [PubMed: 16614256] 
195. Wade KC, Benjamin DK Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B, et al. Fluconazole 
dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis 
J. 2009; 28(8):717–23. [PubMed: 19593252] 
196. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am. 
2006; 20(3):679–97. [PubMed: 16984875] 
Stockmann et al. Page 32
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
197. Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battaglia S, et al. Itraconazole for 
experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with 
cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in 
plasma. Antimicrob Agents Chemother. 1994; 38(6):1303–8. [PubMed: 8092829] 
198. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations 
and better clinical response rates than the capsule formulation in acquired immunodeficiency 
syndrome patients with candidosis. J Clin Pathol. 1997; 50(6):477–80. [PubMed: 9378812] 
199. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with 
itraconazole. Am J Med. 1989; 86(6 Pt 2):791–800. [PubMed: 2543220] 
200. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for 
nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol. 
1990; 23(3 Pt 2):593–601. [PubMed: 2170479] 
201. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for 
cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989; 149(10):2301–8. [PubMed: 
2552949] 
202. Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin. 2013; 29(Suppl 
4):13–8.
203. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. 
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 
2007; 356(4):335–47. [PubMed: 17251530] 
204. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, et al. Safety of long-
term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect 
Dis. 2006; 42(12):1726–34. [PubMed: 16705579] 
205. Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. 
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other 
coadministered agents. Clin Infect Dis. 2009; 48(10):1441–58. [PubMed: 19361301] 
206. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei 
infection among patients with bone marrow transplantation and neutropenia treated 
prophylactically with fluconazole. N Engl J Med. 1991; 325(18):1274–7. [PubMed: 1669837] 
207. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in nonalbicans Candida species. Drug 
Resist Updat. 1999; 2(1):9–14. [PubMed: 11504464] 
208. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, et al. Fluconazole 
resistant opportunistic oropharyngeal Candida and non-Candida yeast-like isolates from HIV 
infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci. 2008; 8(3):142–8. 
[PubMed: 19357740] 
209. Millon L. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus 
positive patients: persistence of Candida albicans strains with the same genotype. J Clin 
Microbiol. 1992; 32(4):1115–8.
210. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of 
antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob 
Agents Chemother. 2009; 53(12):5026–34. [PubMed: 19786600] 
211. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, et al. Changes in 
susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 
2004; 53(1):74–80. [PubMed: 14657086] 
212. Hof H. A new, broad-spectrum azole antifungal: posaconazole—mechanisms of action and 
resistance, spectrum of activity. Mycoses. 2006; 49(Suppl 1):2–6. [PubMed: 16961575] 
213. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 
2007; 356(14):1481–3.
214. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 
14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus 
fumigatus. Antimicrob Agents Chemother. 2003; 47(3):1120–4. [PubMed: 12604551] 
215. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. 
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of 
Stockmann et al. Page 33
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
genetically related resistant isolates from domiciles. Clin Infect Dis. 2013; 57(4):513–20. 
[PubMed: 23667263] 
216. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, et al. Factors 
associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008; 
47(9):1176–84. [PubMed: 18808352] 
217. Denning DW, Bowyer P. Voriconazole resistance in Aspergillus fumigatus: should we be 
concerned? Clin Infect Dis. 2013; 57(4):521–3. [PubMed: 23667265] 
218. Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole 
and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother. 2007; 51(9):
3457–8. [PubMed: 17576835] 
219. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. Efficacy and 
pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive 
aspergillosis. J Antimicrob Chemother. 2013; 68(2):385–93. [PubMed: 23129729] 
220. Prasad PA, Coffin SE, Leckerman KH, Walsh TJ, Zaoutis TE. Pediatric antifungal utilization: new 
drugs, new trends. Pediatr Infect Dis J. 2008; 27(12):1083–8. [PubMed: 18989239] 
221. Hoffman JA, Walsh TJ. Echinocandins in children. Pediatr Infect Dis J. 2011; 30(6):508–9. 
[PubMed: 21587028] 
222. Astellas Pharma US, Inc. FDA approves pediatric indication for Astellas’ MYCAMINE® 
(micafungin sodium) for injection. 2013. http://www.astellas.us/docs/mycamine.pdf Accessed 27 
Nov 2013.
223. Larru B, Zaoutis TE. Newer antifungal agents. Curr Opin Pediatr. 2013; 25(1):110–5. [PubMed: 
23263025] 
224. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a 
comparison. Drugs. 2011; 71(1):11–41. [PubMed: 21175238] 
225. Simitsopoulou M, Peshkova P, Tasina E, Katragkou A, Kyrpitzi D, Velegraki A, et al. Species-
specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: 
characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 2013; 
57(6):2562–70. [PubMed: 23529739] 
226. Pieroni KP, Nespor C, Poole RL, Kerner JA Jr, Berquist WE. Echinocandin and ethanol lock 
therapy treatment of fungal catheter infections. Pediatr Infect Dis J. 2013; 32(3):289–91. 
[PubMed: 23076381] 
227. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, et al. Disposition of 
caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents 
Chemother. 2004; 48(3):815–23. [PubMed: 14982770] 
228. Undre NA, Stevenson P, Freire A, Arrieta A. Pharmacokinetics of micafungin in pediatric patients 
with invasive candidiasis and candidemia. Pediatr Infect Dis J. 2012; 31(6):630–2. [PubMed: 
22301478] 
229. Benjamin DK Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, et al. Safety and 
pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for 
invasive fungal infections. Antimicrob Agents Chemother. 2006; 50(2):632–8. [PubMed: 
16436720] 
230. Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical 
implications. J Antimicrob Chemother. 2010; 65(6):1108–18. [PubMed: 20335190] 
231. Moriyama B, Henning SA, Penzak SR, Walsh TJ. The post-antifungal and paradoxical effects of 
echinocandins against Candida spp. Future Microbiol. 2012; 7(5):565–9. [PubMed: 22568712] 
232. Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, et al. Results from a 
prospective, international, epidemiologic study of invasive candidiasis in children and neonates. 
Pediatr Infect Dis J. 2012; 31(12):1252–7. [PubMed: 22982980] 
233. Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, et al. 
Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: 
substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008; 27(9):820–6. [PubMed: 
18679151] 
Stockmann et al. Page 34
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
234. Undre N, Stevenson P, Baraldi E. Pharmacokinetics of micafungin in HIV positive patients with 
confirmed esophageal candidiasis. Eur J Drug Metab Pharmacokinet. 2012; 37(1):31–8. 
[PubMed: 21956255] 
235. Zhao W, Hope WW, Manzoni P, Jacqz-Aigrain E. Optimizing micafungin dosing in children. The 
Pediatric infectious disease journal. 2012; 31(11):1211–2. author reply 1212. [PubMed: 
23069801] 
236. Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sanchez PJ, Kaufman D, et al. Safety and 
pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010; 87(1):
93–9. [PubMed: 19890251] 
237. Watt KM, Cohen-Wolkowiez M, Ward RM, Benjamin DK Jr. Commentary: pediatric antifungal 
drug development: lessons learned and recommendations for the future. Pediatr Infect Dis J. 
2012; 31(6):635–7. [PubMed: 22414903] 
238. Tapisiz A. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal 
infections? Expert Rev Anti infect Ther. 2011; 9(3):339–46. [PubMed: 21417873] 
239. Wilke MH. Invasive fungal infections in infants-focus on anidulafungin. Clin Med Insights 
Pediatr. 2013; 7:7–11. [PubMed: 23641173] 
240. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob 
Chemother. 2008; 61(1):17–25. [PubMed: 17999982] 
241. Jans J, Bruggemann RJ, Christmann V, Verweij PE, Warris A. Favorable outcome of neonatal 
cerebrospinal fluid shunt-associated Candida meningitis with caspofungin. Antimicrob Agents 
Chemother. 2013; 57(5):2391–3. [PubMed: 23439643] 
242. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. 
Drug Resist Updat. 2003; 6(4):197–218. [PubMed: 12962685] 
243. Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, et al. Concomitant 
cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005; 
45(8):954–60. [PubMed: 16027407] 
244. Saner F, Gensicke J, Rath P, Fruhauf N, Gu Y, Paul A, et al. Safety profile of concomitant use of 
caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection. 2006; 34(6):
328–32. [PubMed: 17180587] 
245. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole 
antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 
2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for 
characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 
2013; 51(8):2571–81. [PubMed: 23720791] 
246. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk 
Manag. 2007; 3(1):71–97. [PubMed: 18360617] 
247. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical 
breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and 
microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011; 
14(3):164–76. [PubMed: 21353623] 
248. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of 
decreased susceptibility and resistance to echinocandins among fluconazole-resistant 
bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012; 50(4):1199–203. [PubMed: 
22278842] 
249. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. 
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence 
of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013; 
56(12):1724–32. [PubMed: 23487382] 
250. Mori M. Nationwide survey of treatment for pediatric patients with invasive fungal infections in 
Japan. J Infect Chemother. 2013; 19(5):946–50. [PubMed: 23732309] 
251. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future 
directions. Clin Infect Dis. 1996; 22(Suppl 2):S133–44. [PubMed: 8722841] 
Stockmann et al. Page 35
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
252. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy 
and distribution of lipid formulations of amphotericin B in experimental Candida albicans 
infection of the central nervous system. J Infect Dis. 2000; 182(1):274–82. [PubMed: 10882607] 
253. Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, et al. 
Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid 
formulations. Antimicrob Agents Chemother. 2006; 50(10):3418–23. [PubMed: 17005824] 
254. Hoesley C, Dismumkes WE. Overview of oral azole drugs as systemic antifungal therapy. Semin 
Respir Crit Care Med. 1997; 18(3):301–9.
255. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000; 30(4):653–7. [PubMed: 
10770726] 
256. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol. 1999; 141(Suppl 
56):26–32. [PubMed: 10730911] 
257. Lexi-Comp. Drug interactions handbook, and drug interactions software. http://www.lexi.com/
institutions/products/pda/lexi-drugs-lexi-interact/ Accessed 23 Nov 2013.
Stockmann et al. Page 36
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Key Points
The development of dosing recommendations for children with invasive fungal infections 
is complicated by non-linear growth and the maturation of organ function.
Pharmacokinetic and pharmacodynamic relationships established in vitro and in murine 
models have been confirmed in paediatric clinical trials for several antifungal agents.
Therapeutic drug monitoring should be considered for antifungal agents that exhibit high 
inter-individual variability and a strong association between plasma concentrations and 
efficacy and/or toxicity (e.g. voriconazole).
Further research is need in the design and optimisation of combination antifungal 
regimens.
Stockmann et al. Page 37
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
The four most common classes of systemic antifungal agents used in the treatment of 
invasive fungal infections and their mechanisms of action
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Fig. 2. 
Antifungal pharmacodynamics in murine models of invasive candidiasis. a Amphotericin B 
dose fractionation studies for three dosing intervals and the log10 colony-forming units per 
gram of kidney in a neutropenic mouse model of disseminated candidiasis (data from Andes 
et al. [15]). b Flucytosine dose fractionation studies for four dosing intervals and the mean 
Candida density in the kidneys of neutropenic mice (data from Andes and van Ogtrop [12]). 
c Fluconazole dose fractionation studies for three dosing intervals and mean fungal density 
in the kidneys of mice with invasive candidiasis (data from Louie et al. [13]). d 
Anidulafungin dose fractionation studies for four dosing intervals and the mean change in 
Candida density in the kidneys of neutropenic mice with invasive candidiasis (data from 
Andes [24]). CFU colony-forming units, qx hrs every x hours
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Table 1
US FDA-approved agents for the treatment of invasive fungal infections in children
Pharmacological agent Approved indication Approved dose
Azoles
 Fluconazole Treatment of oropharyngeal and oesophageal candidiasis and 
cryptocococcal meningitis
Initial: 6 mg/kg/dose od 
Maintenance: 3–12 mg/kg/dose 
od Maximum daily dose: 600 
mg/day
 Itraconazole Treatment of blastomycosis (pulmonary and extrapulmonary), 
histoplasmosis (including chronic cavitary pulmonary disease and 
disseminated, non-meningeal histoplasmosis) and aspergillosis 
(pulmonary and extrapulmonary) in patients who are intolerant of or 
who are refractory to amphotericin B therapy
3–5 mg/kg/dose od
 Posaconazole Treatment of oropharyngeal candidiasis, including oropharyngeal 
candidiasis refractory to itraconazole and/or fluconazole
400 mg bid
 Voriconazole Treatment of invasive aspergillosis; candidaemia in non-neutropenic 
patients; disseminated Candida infections in skin, the abdomen, 
kidney, bladder wall and wounds; oesophageal candidiasis; and 
serious fungal infections caused by Scedosporium apiospermum and 
Fusarium spp., including Fusarium solanì, in patients intolerant of or 
refractory to other therapies
9 mg/kg/dose bid
Maximum single dose: 350 
mg/dose
Echinocandins
 Caspofungin Empirical therapy for presumed fungal infections in febrile, 
neutropenic patients; treatment of candidaemia and the following 
Candida infections: intra-abdominal abscesses, peritonitis and pleural 
space infections; treatment of oesophageal candidiasis; and treatment 
of invasive aspergillosis in patients who are refractory to or intolerant 
of other therapies
Initial: 70 mg/m2/dose od 
Maintenance: 50 mg/m2/dose 
od Maximum daily dose: 70 
mg/m2/day
 Micafungin Treatment of patients with candidaemia, acute disseminated 
candidiasis, Candida peritonitis and abscesses; treatment of patients 
with oesophageal candidiasis
2 mg/kg od
Maximum daily dose: 100 
mg/day
Polyenes
 Amphotericin B deoxycholate Treatment of potentially life-threatening invasive fungal infections: 
aspergillosis, cryptococcosis, North American blastomycosis, 
systemic candidiasis, coccidioido-mycosis, histoplasmosis, 
zygomycosis, including mucormycosis due to susceptible species of 
the genera Absìdìa, Mucor and Rhizopus, and infections due to 
related susceptible species of Conìdìobolus and Basìdìobolus, and 
sporotrichosis
Initial: 0.25–0.5 mg/kg/dose od 
Maintenance: 0.25–1 mg/kg/
dose od Maximum daily dose: 
1.5 mg/kg/day
 Liposomal amphotericin B 
(AmBisome)
Empirical therapy for presumed fungal infection in febrile, 
neutropenic patients; treatment of cryptococcal meningitis in HIV-
infected patients; treatment of patients with Aspergillus, Candida 
and/ or Cryptococcus infections refractory to amphotericin B 
deoxycholate, or in patients in whom renal impairment or 
unacceptable toxicity precludes the use of amphotericin B 
deoxycholate; and treatment of visceral leishmaniasis
3–5 mg/kg/dose od
 Amphotericin B lipid complex 
(Abelcet®)
Treatment of invasive fungal infections in patients who are refractory 
to or intolerant of conventional amphotericin B therapy
3–5 mg/kg/dose od
 Amphotericin B colloidal 
dispersion (Amphotec®)
Treatment of invasive aspergillosis in patients where renal 
impairment or unacceptable toxicity precludes the use of 
amphotericin B deoxycholate in effective doses, and in patients with 
invasive aspergillosis where prior amphotericin B deoxycholate 
therapy has failed
3–1 mg/kg/dose od
Pyrimidine analogues
 Flucytosine Treatment of serious infections caused by susceptible strains of 
Candida and/or Cryptococcus
50–150 mg/kg qid
bid twice daily, od once daily, qid four times daily
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Table 2
Structural and pharmacokinetic properties of amphotericin B formulations among adults with invasive fungal 
infections
Property Amphotericin B deoxycholate Lipidic formulations
Amphotericin B 
lipid complex
Amphotericin B 
colloidal 
dispersion
Liposomal amphotericin B
Formulation properties
 Size (nm) 0.035 1,600–11,000 120–140 80
 Structure Micelles Ribbon-like Disk-like Liposomes
Plasma pharmacokinetic properties
 Dose (mg/kg) 1.0 5.0 5.0 5.0
 Maximum plasma 
concentration (mg/L) [mean ± 
SD]
5.36 ± 0.82 1.58 ± 0.32 7.66 ± 4.51 46.7 ± 2.81
 Minimum plasma concentration 
(mg/L) [mean ± SD]
0.34 ± 0.07 0.24 ± 0.08 0.37 ± 0.12 26.4 ± 4.99
 Area under the concentration–
time curve from time 0 to 24 h 
(mg·h/L) [mean ± SD]
17.4 ± 1.21 11.8 ± 3.09 20.4 ± 4.10 887 ± 59
 Apparent volume of 
distribution at steady state (L/kg) 
[mean ± SD]
0.81 ± 0.10 6.35 ± 1.25 3.61 ± 0.64 0.10 ± 0.01
 Total plasma clearance (L/kg/h) 
[mean ± SD]
0.041 ± 0.00 0.315 ± 0.11 0.187 ± 0.04 0.001 ± 0.00
Pulmonary pharmacokinetic properties
 Dose (mg/kg) 1.0 5.0 5.0 5.0
 Concentration in lung tissue 
(μg/g) [mean ± SD]
2.71 ± 1.22 16.26 ± 1.62 6.29 ± 1.17 6.32 ± 0.57
 Concentration in epithelial 
lining fluid (mg/L) [mean ± SD]
0.44 ± 0.13 0.90 ± 0.28 0.68 ± 0.27 2.28 ± 1.43
 Concentration in pulmonary 
alveolar macrophages (mg/L) 
[mean ± SD]
8.92 ± 2.84 89.1 ± 37.0 5.43 ± 1.75 7.52 ± 2.50
Tissue penetration properties
 Plasma concentration (mg/L) 
[mean ± SD]
1.82 ± 0.07 0.93 ± 0.03 0.85 ± 0.01 62.90 ± 0.99
 CSF concentration (mg/L) 
[mean ± SD]
0.023 ± 0 0.022 ± 0 0.014 ± 0.007 0.024 ± 0.001
 Brain concentration (μg/g) 
[mean ± SD]
0.18 ± 0.03 0.27 ± 0.02 0.22 ± 0.02 1.99 ± 0.33
Data from Hiemenz and Walsh [251], Groll et al. [252, 253]
CSF cerebrospinal fluid
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Table 3
Pharmacokinetic properties of fluconazole, itraconazole, voriconazole and posaconazole in adults
Property Fluconazole Itraconazolea Voriconazole Posaconazole
Dose 6–12 mg/kg/day 200 mg bid 6 mg/kg q12 h for 2 
doses, then 4 mg/kg 
q12 h
600–800 mg/day in 
divided doses
Formulation properties
 Route of administration IV infusion, PO 
capsules, PO 
solution
IV infusion, PO 
capsules, PO 
solution
IV infusion, PO 
capsules, PO 
suspension
PO suspension
 Oral bioavailability (%) >80 50 90
 Protein binding (%) 11–13 >99 58 98–99
Pharmacokinetic properties
 Maximum concentration (μg/L) 6–20 0.5–2.3 3.0–4.6 1.5–2.2
 Area under the concentration– time 
curve (mg·h/L)
400–800 29.2 20.3 8.9
 Terminal elimination half-life (h) 22–35 24–42 6 25
 Unchanged drug in urine (%) 80 1–10 <2 <2
 Primary route of metabolism Hepatic (minor) Hepatic Hepatic Hepatic (moderate)
 Primary route of elimination Renal Hepatic Renal Faeces
Bodily fluid penetration properties
 CSF penetration (%) 80 <10 60 –
 Vitreous penetration (%) 28 10 38 26
Data from Lewis [117] and Lipp [158]
bid twice daily, CSF cerebrospinal fluid, IV intravenous, PO oral, q12 h every 12 h
a
Data are for the oral solution formulation of itraconazole
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Table 4
Fluconazole, itraconazole, voriconazole and posaconazole drug–drug interactions
Property Fluconazole Itraconazole Voriconazole Posaconazole
Decreased absorption of azoles
 Antacids X
 Didanosine, oral X X X X
 Histamine H2 receptor antagonists X
 Omeprazole X X X X
 Sucralfate X X X
Increased metabolism of azoles
 Carbamazepine X X X X
 Isoniazid X X
 Phenobarbital X X X
 Phenytoin X X X X
 Rifampin (rifampicin) X X X X
Increased plasma concentration of coadministered drug
 Ado-trastuzumab emtansine X X X
 Alfuzosin X X X
 Aliskiren X
 Alprazolam X
 Apixaban X X X
 Astemizole X
 Atazanavir X
 Atorvastatin X
 Avanafil X X X
 Axitinib X X X
 Barbiturates X
 Bosutinib X X X X
 Cabozantinib X X X
 Cisapride X X X X
 Citalopram X
 Conivaptan X X X X
 Crizotinib X X X
 Darunavir X
 Dihydroergotamine X X X
 Dofetilide X X X X
 Dronedarone X X X
 Efavirenz X
 Eletriptan X X
 Eplerenone X X X
 Ergoloid mesylates X X X
 Ergonovine X X X
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Property Fluconazole Itraconazole Voriconazole Posaconazole
 Ergotamine X X X
 Everolimus X X X
 Halofantrine X X X
 Imatinib X X X
 Ivabradine X X X X
 Lapatinib X X X
 Lomitapide X X X X
 Lopinavir X
 Lovastatin X X X
 Lurasidone X X
 Macitentan X X X
 Methadone X X
 Methylergonovine X X X
 Midazolam X
 Mifepristone X X
 Nevirapine X
 Nilotinib X X X
 Nisoldipine X X X
 Ospemifene X
 Pimozide X X X X
 Pomalidomide X X X
 Proton pump inhibitors X
 Quinidine X X X X
 Ranolazine X X X X
 Regorafenib X X X
 Rifamycin derivatives X
 Ritonavir X
 Rivaroxaban X X X
 Salmeterol X X X
 Silodosin X X X
 Simvastatin X X X
 Sirolimus X X
 St John’s wort X
 Tamsulosin X X X
 Terfenadine X
 Ticagrelor X X X
 Tolvaptan X X X X
 Topotecan X
 Toremifene X X X
 Triazolam X
 Ulipristal X X X X
 Vemurafenib X X X
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Property Fluconazole Itraconazole Voriconazole Posaconazole
 Vincristine, liposomal X X X
Data from Hoesley and Dismumkes [254], Dismukes [255], Katz [256] and the Lexi-Comp Drug Interactions Handbook and Drug Interactions 
Software [257]
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